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ABSTRACT 
  
Breast cancer, osteoporosis, and coronary heart disease (CHD) are three 
major threats to women’s health. Postmenopausal women with breast cancer are 
also at high risk for osteoporosis and CHD. Adjuvant tamoxifen therapy is not 
only an effective treatment for breast cancer, but has been shown to have a 
beneficial effect on bone and the cardiovascular system. Although tamoxifen has 
been convincingly demonstrated to be able to preserve bone mineral density 
(BMD), an unexpected increase of risk of fractures in patients treated with 
tamoxifen has been reported. The findings of the association of tamoxifen and 
CHD from previous studies were either borderline or inconsistent. To clarify the 
discrepancy between BMD and fractures and test the potential beneficial effect of 
tamoxifen on CHD, I conducted a series of retrospective studies in 
postmenopausal women with breast cancer who participated in the Cancer 
Surveillance in HMO Administrative Data (IMPACT study) or the Study of 
Osteoporotic Fractures (SOF).  
 
In patients who participated in the IMPACT study, I demonstrated that the 
association of tamoxifen and fracture incidence varied at different skeletal sites. 
Although the association of tamoxifen and fractures in the spine (HR=0.40, 95% 
CI: 0.09-1.85), wrist (HR=2.49, 95% CI: 0.88-7.06), and total body (HR=0.87, 
95% CI: 0.49-1.55) was inconclusive, tamoxifen was associated with an apparent 
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reduction of the risk of hip fracture (HR=0.41, 95% CI: 0.17-1.03, p=0.0565). 
Importantly, the pattern of observed association of tamoxifen with the risks of 
fractures among postmenopausal women with breast cancer is consistent with its 
widely reported preserving effect on bone mineral density.  
 
Using SOF data, I found that the association between BMD and fractures 
in women with breast cancer varied at different skeletal sites, and type of BMD 
measured. Non-specific BMD was not associated with hip fracture (HR=1.12; 
95% CI: 0.78, 1.59). Site-specific BMD was more likely linked with hip fracture 
(HR=1.43, 95% CI: 0.99, 2.08) while change in BMD did not predict hip fracture 
(HR=1.05; 95% CI: 0.63, 1.72). The association of spine morphometric fracture 
with either non-specific or spine-specific BMD was similar (OR=1.40; 95% CI: 
1.04, 1.90; OR=1.35, 95% CI: 0.99, 1.85, respectively). Overall, the association 
of BMD and fracture in elderly women with breast cancer is weak. Only site-
specific BMD appears to have a consistently modest association with fractures in 
the corresponding skeletal sites.  
 
In the IMPACT study population, compared to patients without tamoxifen, 
the overall incidence of CHD in tamoxifen-treated patients was lower (adjusted 
HR=0.60, 95% CI: 0.40-0.88). For each year of tamoxifen use, there was a 
statistically significant decrease in the risk of CHD (HR=0.90, 95% CI: 0.82-0.98). 
Further analyses categorized by length of tamoxifen use showed that an 
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apparent association with a decreased CHD risk was found in patients who 
received tamoxifen for two to five years (HR=0.54, 95% CI: 0.33-0.86). No 
association was detected after the discontinuation of tamoxifen therapy. 
 
In summary, I detected a possible benefit associated with tamoxifen on 
fractures in the hip, the most common fracture site. I also found that BMD did not 
predict osteoporotic fractures well in postmenopausal women with breast cancer. 
In addition, I demonstrated that tamoxifen was associated with a reduced risk of 
CHD in postmenopausal women with breast cancer in a dose-dependent manner. 
An apparent benefit was found in those patients who received tamoxifen therapy 
for at least two years.  
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CHAPTER I 
 
STUDY BACKGROUND 
 
1.1 Breast cancer, osteoporosis, and CHD in postmenopausal women 
 
Breast cancer is the most common cancer and the second leading cause 
of cancer death in women. In the United States alone, it is estimated that a total 
of 182,460 new female cases and 40,480 deaths will occur in 2008.1 However, 
over the last decade a steady decline in breast cancer deaths has been observed 
due to advancements in breast cancer diagnosis and treatment. The majority of 
these women are over the age of 65 and can expect a lengthy period of breast 
cancer survivorship. 
 
Osteoporosis, a progressive process of bone mass loss, is another lethal 
disease threatening women’s health. About 25% of postmenopausal white 
women suffer from osteoporosis.2-4 More importantly, 1.3 million fractures are 
associated with osteoporosis in the United States each year, which leads to 
substantial morbidity and mortality. Therefore, osteoporosis may be a major 
additional concern in postmenopausal women with breast cancer. Risk of 
osteoporosis is enhanced by a combination of female gender, older age, 
hormonal change, and the cancer itself. Increased bone loss in women with 
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breast cancer may result from chemotherapy 5 and from adjuvant therapy agents 
such as aromatase inhibitors.6, 7 Thus, in addition to risk of fracture due to loss of 
BMD, women with breast cancer may be at additional risk of fractures because of 
these cancer related factors.  
 
 Typically considered as a disease that affects mainly men, CHD is actually 
the leading cause of death in women in the United States. While fewer women 
than men suffer from CHD before age 50, the difference dramatically decreases 
in postmenopausal women. CHD causes the death of 283,886 females annually 
compared with 40,460 deaths from breast cancer. 8 Eventually, about one third of 
women die from CHD, causing the deaths of four times as many women as 
breast cancer.9  
  
 Because of the high prevalence of breast cancer, osteoporosis, CHD, 
postmenopausal women with breast cancer are at an increased risk of morbidity 
and mortality. For these patients, anti-tumor effects should not be the only factor 
considered when selecting breast cancer treatment. It is imperative, when 
possible, to take into consideration the potential additional impact of treatment on 
osteoporosis and CHD in order to improve their survivorship and overall health.  
 
1.2 Tamoxifen therapy in postmenopausal women with breast cancer 
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 Breast cancer is one of the most treatable cancers. Although more than 
10% of women develop breast cancer in their lifetime, only about 4% of them die 
from the disease. Effective treatment choices, including surgery, hormonal 
therapy, radiation, and chemotherapy, save the lives of most breast cancer 
patients. Among these, hormonal therapy is a unique and very effective option in 
the treatment of breast cancer. It specifically suppresses hormone-induced tumor 
cell growth. Since the majority of women with breast cancer have positive-
hormone-receptor status,10 hormonal therapy often becomes the first adjuvant 
therapy after primary tumor therapy.  
  
 The most commonly used hormonal therapies are SERMs (Selective 
Estrogen Receptor Modulators). Unlike estrogen, the SERMs are a group of 
chemically synthetic agents that lack the steroid structure. However, they can still 
bind to estrogen receptors and exert tissue-specific actions. In general, the 
SERMs act as estrogen antagonists by competing with estrogen to bind to 
estrogen receptors in breast cells, 11, 12 thereby suppressing the cancer cell 
proliferation stimulated by estrogen. In other tissues such as bone, uterus, and 
the cardiovascular system, SERMS are estrogen agonists and exhibit some 
estrogen-like effects.13-16  
 
 The most successful SERMs agent in the treatment of breast cancer is 
tamoxifen. Since its introduction into clinical practice in 1978, tamoxifen has been 
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shown to effectively reduce the risk of breast cancer recurrence and improve 
survival in women at all stages of breast cancer. The summarized findings from a 
meta-analysis of 55 trials in 37,000 women with breast cancer treated with 
tamoxifen for five years demonstrated a reduction of 47% in the rate of 
recurrence. 17 Tamoxifen reduces annual death of patients with early breast 
cancer by 31% after five years of standard treatment, according to an overview of 
194 randomized trials of adjuvant chemotherapy or hormonal therapy. 18 In 
addition to its high efficacy, tamoxifen is well tolerated with few severe adverse 
effects. For three decades, tamoxifen has been the choice for hormonal therapy 
both in pre and post-menopausal women as well as in men with breast cancer. 17, 
19, 20 
 
Recently, another type of hormonal therapy agent, aromatase inhibitor, 
has emerged as an efficacious treatment for breast cancer. Unlike tamoxifen, 
which binds to estrogen receptors, aromatase inhibitors block aromatase activity, 
and therefore decrease estrogen levels both in the breast and in circulation. 
Several clinical trials have demonstrated the anti-tumor superiority of the third 
generation aromatase inhibitors over tamoxifen. Based on this evidence, the 
National Comprehensive Cancer Network (NCCN) guidelines (2006) recommend 
the use of the third-generation aromatase inhibitors for breast cancer treatment 
of postmenopausal women. 21 Tamoxifen is still the first choice of hormonal 
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therapy treatment in premenopausal women but no longer for postmenopausal 
breast cancer patients.  
 
 While it is reasonable to replace tamoxifen with aromatase inhibitors in 
terms of cancer treatment, it may be questionable to apply it in postmenopausal 
women with breast cancer who are also at high risk of other diseases such as 
CHD. It is particularly problematic if such patients have osteopososis since 
aromatase inhibitors have been clearly linked to an increased risk of fractures.8, 9 
Thus, as the treatment of early stage breast cancer begins to leave tamoxifen 
and shift to aromatase inhibitors, a comprehensive assessment of the effects of 
tamoxifen outside of the paradigm of anti- tumor property is critical to make the 
most well-informed decisions for breast cancer treatment. 
 
The common adverse events of tamoxifen treatment are hot flashes and 
vaginal dryness. The more severe, yet less common, side effects are 
thromboembolic events such as venous thromboses and pulmonary emboli. 
Increased risk of endometrial cancer is also a concern in patients treated with 
tamoxifen. However, tamoxifen has also been reported to have beneficial side 
effects, including the protection of bone against osteoporosis and the heart from 
cardiovascular events. These beneficial effects are especially important for 
postmenopausal women since they are at high risk of osteoporosis and CHD. 
Clarification of the quality and quantity of the benefit associated with tamoxifen 
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on bone and heart health in addition to its anti-tumor effect will help guide the 
clinical practice in breast cancer treatment among postmenopausal women.  
 
 
1.3 Bone health in postmenopausal women with breast cancer: how 
protective is tamoxifen? (published previously in Cancer Treat Rev 
2007;33:506-13) 
 
(1) Abstract 
 
 Breast cancer is a leading threat to women’s health. Tamoxifen, the most 
successful selective estrogen receptor modulator, has been used in hormonal 
therapy for three decades. Along with its therapeutic effect on breast cancer, 
tamoxifen also demonstrates potential benefits for bone health. However, the 
extent and quality of such benefits have not been systematically evaluated. We 
conducted a comprehensive literature search and identified 27 peer-reviewed 
articles investigating the relationship between tamoxifen and bone health in 
postmenopausal women with early stage breast cancer. The majority of studies 
reported that tamoxifen therapy alone protected against the loss of spinal bone 
mineral density. The bones in the hip also benefited from tamoxifen treatment 
while there was no evidence demonstrating tamoxifen’s protection against bone 
loss in the wrist. When tamoxifen was combined with chemotherapy, it was found 
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to partially prevent or reverse the bone loss resulting from chemotherapy. 
Patients with a history of hormone replacement therapy experienced bone loss 
while patients without the history had increased bone mineral density during 
tamoxifen therapy. Despite an apparent impact of tamoxifen on bone mineral 
density, the few available studies of tamoxifen and bone fractures appear to 
suggest no protective effect but an increase in fracture incidence. More 
investigation is necessary to clarify the discrepancy between bone mineral 
density and fracture in postmenopausal breast cancer patients treated with 
tamoxifen. 
 
Key Words: Tamoxifen; Breast cancer; Osteoporosis; Bone density. 
 
(2) Introduction 
 
Breast cancer is the most common cancer and the second leading cause 
of cancer death in women. In the United States alone, it is estimated that a total 
of 274,900 new female cases and 40,970 deaths will occur in 2006.1 However, 
over the last decade a trend of a steady decline in breast cancer deaths has 
been observed due to advancements in breast cancer diagnosis and treatment. 
Most of the women currently diagnosed with breast cancer are over the age of 65 
and can expect lengthy periods of breast cancer survivorship. 
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Osteoporosis, a progressive process of bone mass loss, is a potential 
concern in these older breast cancer patients. The risk of osteoporosis is 
enhanced by a combination of female gender, older age, hormonal change, and 
the cancer itself. Increased bone loss in women with breast cancer may result 
from chemotherapy 5 and from adjuvant therapy agents such as aromatase 
inhibitors.6, 7  
The majority of breast cancer tumors in postmenopausal women are 
hormone receptor positive 10 and therefore sensitive to hormone deprivation 
therapy. Selective estrogen receptor modulation (SERM) was a revolutionary 
development in the history of breast cancer treatment. It suppresses cancer cells 
in the breast tissue by its anti-estrogenic effect while acting as an estrogen 
analog in other tissues.11-15 Tamoxifen is the most commonly used SERM drug in 
hormonal therapy for breast cancer and has been a major component of 
treatment for women with hormone receptor positive breast cancer for three 
decades. The National Comprehensive Cancer Network (NCCN) guidelines 22 
recommend the use of adjuvant endocrine therapy in women with hormone 
receptor-positive breast cancer. While it has been clearly demonstrated that 
tamoxifen increases the survival rate in breast cancer patients, it has some 
severe side effects such as venous thrombosis and endometrial cancer due to its 
estrogen-like effect.23-26 However, tamoxifen has also been reported to have 
beneficial side effects, including the protection of bone from osteoporosis 
because of this estrogenic action.15 
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Since both breast cancer and osteoporosis strike mainly women, 
especially postmenopausal women, postmenopausal women with breast cancer 
might receive an extra benefit from tamoxifen therapy. As the treatment of early 
stage breast cancer begins to leave tamoxifen and shift to aromatase inhibitors, it 
is important to clarify the amount of protection against bone loss that tamoxifen 
has been found to confer in postmenopausal women with breast cancer. It is 
particularly important to quantify the extent to which tamoxifen prevents fractures 
in these patients. To that end, we performed a systematic review of the literature 
to clarify the evidence on the effectiveness of the tamoxifen on bone health. 
 
(3) Methods 
 
1. Literature search strategy 
Bone health has been documented by a variety of measures including 
serum calcium level, the biomarkers of bone metabolism, bone mineral density 
(BMD), and bone fracture. We focused on BMD and fracture, the two most 
clinically relevant bone health indicators. A PubMed search was made by a 
combination of MeSH terms (breast neoplasm and tamoxifen plus bone or 
osteoporosis or bone density or bone fracture), limited to human, female, adults 
(≥45 years old), and published in English. Initially, three hundred and seven 
articles were identified. Forty-six reviews were first excluded. Of the remaining 
261 articles, 229 were either not relevant to bone health, without appropriate 
controls or studied the impact of aromatase inhibitors on bone and therefore 
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were not of interest for this review. After further excluding studies in healthy 
women (N=2), premenopausal women (N=1), and articles not available in full text 
(N=3), 26 articles were identified. Searching related studies and the references of 
identified articles resulted in identifying one additional study. Finally, 27 articles 
were included in this study (Figure 1).  
 
2. Methods used to measure bone density  
Bone mineral density, as recommended by the World Health Organization, 
is the gold standard for bone loss measurement. In the studies reviewed, three 
methods were adopted for measuring BMD. Most studies conducted in the 
1980’s and early 1990’s used photon absorptiometry (PA), a technique typically 
based on the transmission of isotope I-125 or Gd-153 for bone scanning. 
Although it generally produces a good and reproducible result, the amount of 
radiation that a patient is exposed to is a concern. Quantitative computed 
tomography is a good alternative to photon absorptiometry. It is more precise and 
sensitive in detecting BMD change. However, it can only be used for spinal bone 
density measurement. The high cost also makes it less accessible.  
Dual energy X-ray (DXA) absorptiometry is currently the most widely used 
technology for BMD measure. It depends on a safer X-ray instead of an isotope 
source for bone mass detection. Because of its low radiation exposure, high 
precision, short scan times, and suitability for any skeletal sites including whole 
body scanning, DXA has essentially replaced PA for BMD measure.  
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3. Quality assessment  
Each study was assessed for methodological quality using a checklist 
designed for both randomized and non-randomized studies.27 The checklist 
includes 27 items in five categories (reporting, external validity, internal validity-
bias, internal validity-confounding, and statistical power). The maximal score of 
quality assessment is 32. The highest score achieved by the studies included in 
this review was 23 with an average score of 12.78 (Table 1).  
 
(4) Results 
 
1. Tamoxifen alone 
Changes in spinal BMD. The majority of studies of adjuvant treatment 
using tamoxifen alone focused on changes in spinal BMD. An early investigation 
in 10 postmenopausal breast cancer women treated for one year with tamoxifen 
demonstrated a significant preservation of BMD compared to matched healthy 
women.28 A similar finding was obtained by Ward et al.29 Four other studies that 
used healthy women as controls, showed marginal or no BMD increase.30-33  
To observe BMD change over time, several studies adopted baseline 
value as a control. Ryan conducted a preliminary study in 1991 in eight breast 
cancer patients receiving one year of tamoxifen therapy and noticed a continuous 
increase from 3.6% (6 months) to 4.3% (12 months) in spine BMD in these 
patients.34 Three more studies in the early and mid 1990’s 35-37 also using photon 
absorptiometry, failed to find a significant BMD change over baseline. Using the 
12 
 
most recent BMD measuring technology DXA, Marttunen found a range of 0.4 to 
2% difference in BMD after one year of tamoxifen therapy in 30 patients with 
stage II breast cancer.38, 39 In Japan, Yoneda found a 3.3% increase in BMD at 6 
months and 2.7% at 12 months.40 In the most recent study in the United Kingdom, 
Estell et al reported an intermediate finding from the five-year Anastrozole, 
Tamoxifen, Alone or in Combination (ATAC) trial in postmenopausal women with 
invasive breast cancer: at year two, an increase of 2.2% in lumbar spinal BMD 
was observed.41 However, a recent randomized control trial conducted in 36 
postmenopausal patients with either stage II or stage III breast cancer did not 
find a change in BMD over a three-year period.42 Similarly, no BMD change was 
detected in a recent prospective study in 44 estrogen-receptor-positive patients.43 
Using patients without adjuvant therapy as controls, Kristensen found 
statistically significant BMD differences in 50 patients with early breast cancer 
after two years of tamoxifen therapy.44 Lumbar spine BMD in the tamoxifen 
treatment group increased 2% in the first year and became stable in the following 
year while a steadily decrease to 5% was observed in patients without tamoxifen. 
In a cohort of breast cancer patients (N=111) followed for five years, Resch 
demonstrated a significantly lower BMD in patients without tamoxifen therapy.45  
Love et al conducted a randomized placebo-controlled trial in 140 patients 
with axillary node-negative breast cancer.46, 47 In the first two years after the 
administration of tamoxifen, lumbar spinal BMD increased 0.61% per year in the 
tamoxifen group while it decreased 1.0% per year in placebo group. A further 
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follow-up study examining the BMD change in 62 patients who completed a five 
year regimen revealed a 0.8% BMD increase in the tamoxifen group compared to 
a 0.7% decrease in the placebo group. 
Changes in hip BMD. Ten studies measured the BMD change in the hip 
bone. Marttunen found a 5% BMD increase at Ward’s triangle in a study of 30 
stage II breast cancer patients treated with tamoxifen for one year.38 Rodriguez 
noted a significant BMD increase after one year of treatment with tamoxifen 
alone in the trochanter area of the hip bone in recent research conducted in a 
subgroup of 22 patients.48 Ward et al also observed a 1.4% BMD increase after 
one year of treatment with tamoxifen compared to a 2.3% decrease in healthy 
controls.29 A statistically significant association between tamoxifen therapy and 
BMD change in the hip over two years was observed by Cameraon and his 
colleagues.49 In the ATAC trial, a 1.2% increase of BMD at total hip was 
observed.41 The increased BMD in the hip was not significant or not seen in 
seven other studies.30, 33, 34, 37, 40, 42 Changes in wrist BMD. BMD in the wrist was 
explored in seven studies.31, 32, 35, 36, 44, 46, 50 No significant increase was seen in 
any of these studies. A slower BMD loss was observed in patients with tamoxifen 
in a randomized controlled trial of 50 patients with breast cancer.44 A similar trend 
was seen in the study conducted by Love et al, but was not statistically significant. 
The remaining five studies did not see BMD change.  
 
2. Tamoxifen plus chemotherapy 
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In a study exploring the tamoxifen effect on BMD after chemotherapy, 
Rodriguez found significant BMD increases in both intertrochanter and total hip in 
women who received 12 months of tamoxifen after chemotherapy.48 BMD at 
other sites of the hip such as the femoral neck, trochanter, and Ward’s triangle 
remained stable. Spinal BMD was unchanged as well. When tamoxifen was 
administered with chemotherapy, no BMD change was detected in either the 
spine or forewrist as demonstrated by Love.51 Crandall studied 280 subjects and 
compared joint adjuvant tamoxifen therapy and chemotherapy to a control group 
of healthy women.30 BMD in the spine, hip, and total body was increased, but this 
was not statistically significant.    
 
3. Tamoxifen and hormonal replacement therapy 
Two studies involved the influence of hormonal replacement therapy (HRT) 
on the effect of tamoxifen on BMD. Both investigated the BMD change after three 
years of tamoxifen use. Tiitinen demonstrated a 4.0% spinal BMD decrease in 
patients who had received HRT prior to breast cancer diagnosis while patients 
without an HRT history remained unchanged.31 Saarto had a similar finding of 
spinal BMD, showing a 3.0% decrease for patients with an HRT history and a 
1.2% increase for patients without a HRT history.52 He also found a similar 
pattern of BMD change in the hip, although to a smaller extent.  
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4. Tamoxifen and fractures 
In a large randomized controlled trial (N=1716) directly investigating the 
femoral fractures in postmenopausal breast cancer patients treated with 
tamoxifen for one year, Kristensen et al found a higher incidence in the tamoxifen 
group compared to patients not receiving tamoxifen. Following a cohort of 352 
breast cancer patients in which 79% received either tamoxifen alone or in 
combination with chemotherapy,53 Kanis et al observed an increase in the rate of 
spinal fracture 4.7 times that of healthy controls.54 Findings from both studies 
were statistically significant.  
 
 
(5) Discussion 
 
Tamoxifen has been the dominant hormonal treatment for breast cancer 
patients for three decades. In addition to its efficacy, it has also been perceived 
as having a beneficial effect on bone health. In this review, the majority of 
published studies demonstrated a protective effect of tamoxifen therapy on spinal 
BMD in postmenopausal patients with early stage breast cancer (Figure 2). In the 
hip, the benefit varies depending on the site. The highest BMD increase from 
baseline was found at Ward’s triangle (5%).38 No bone protection was reported in 
the wrist. Studies of the hip and wrist are relatively fewer than those focused on 
the spine. Because the fractures in postmenopausal women caused by 
osteoporosis increase exponentially in the hip, where the outcomes are more 
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serious than from fractures of the spine or wrist, the most important form of 
protection for bone would affect the hip.  
When chemotherapy is included in the treatment of breast cancer, it is 
frequently combined with hormonal therapy. The high toxicity of chemotherapy 
can cause many unwanted outcomes including early menopause and thus an 
increased risk of osteoporosis. In three studies investigating the protective effect 
of tamoxifen on BMD in a combined treatment with chemotherapy,30, 48, 51 one 
showed that tamoxifen reversed the bone loss after chemotherapy.48 This 
protective effect is likely due to tamoxifen’s estrogenic action on bone. When 
tamoxifen is used simultaneously with chemotherapy, such a protection is not 
clear.51 The negative effect of chemotherapy on estrogen may outweigh the 
estrogenic action of tamoxifen.   
Hormone replacement therapy has been a common treatment for 
postmenopausal women. Many patients have a history of HRT use when 
diagnosed with breast cancer. The bone loss caused by discontinuing HRT at the 
time of breast cancer treatment is not fully offset by the effect of tamoxifen on 
BMD, as demonstrated by the studies in this review.42, 52  
Overall, these studies provide convincing evidence that tamoxifen 
preserves BMD at least in the spine and hip in postmenopausal women with 
breast cancer. This protection gradually decreases over time. However, 
tamoxifen therapy after five years still showed a beneficial effect on bones.47 The 
mechanism of the protection is not fully understood. Part of the explanation is the 
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estrogenic action of tamoxifen outside of breast tissue.15 This hypothesis is 
supported by the studies in this review, which demonstrated that a reduced level 
of estrogen by chemotherapy or HRT withdrawal weakened or offset the 
protective effect of tamoxifen on BMD.30, 42, 48, 51, 52 Tamoxifen has also been 
shown to behave differently in premenopausal women by decreasing rather than 
increasing BMD 55-57, indicating a strong influence of estrogen on the effect of 
tamoxifen on bone health. The decrease in bone turnover biomarkers in patients 
treated with tamoxifen further suggests its estrogenic effect.38, 40, 43 Although 
many studies have demonstrated that tamoxifen protects against loss of BMD in 
postmenopausal women with breast cancer, the extent of such protection is not 
clear or consistent. Few studies directly investigated the net BMD increase.44-47, 
50 Most studies used baseline BMD value as the control.  This comparison may 
underestimate the impact of tamoxifen on BMD because BMD naturally 
decreases over time in postmenopausal women (Figure 2). Thus, the full impact 
of tamoxifen on BMD can not be obtained using women as their own controls. 
Similarly, healthy controls are not ideal because the bone mass density and its 
change in normal persons have been found to differ from that of women with 
breast cancer. Depending on their estrogen receptor status and anti-tumor 
therapy received, these patients could have a higher BMD value58 or increased 
bone loss.5-7The scientific benefits of tamoxifen on bone health would be more 
convincing if data were obtained from randomized placebo controlled trials 
directly comparing breast cancer patients with and without tamoxifen.  
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The only two identified studies that directly investigated fractures in 
patients treated with tamoxifen found no beneficial effects but negative impacts 
on both spinal and hip bones,53, 54 compared to breast cancer patients who did 
not receive tamoxifen or to an age matched general population. In fact, the 
fracture risk in overall breast cancer survivors regardless of tamoxifen treatment 
status is not well known.59, 60 This may be partially due to the complexity of 
measuring fracture risk in elderly women. It is difficult to differentiate a disease 
specific fracture from common fractures in the population. Also important is that 
although low BMD has been linked with the likelihood of fracture,61, 62 the change 
in BMD has predicted the fracture risk poorly in patients with osteoporosis after 
raloxifene treatment.63, 64 This may also be true in breast cancer patients treated 
with tamoxifen. In addition, bone health in cancer patients is not only determined 
by bone metabolism, cancer itself is a major contributor. Women with breast 
cancer may be weaker and therefore more likely to fall, leading to a bone fracture. 
Thus, tamoxifen may protect women without breast cancer against fractures as 
demonstrated by the Breast Cancer Prevention Trial (P-1),65 while such 
protection is not evident in breast cancer patients. In the absence of further 
information from randomized trials, clarification of the relationship of tamoxifen 
therapy and fracture in breast cancer patients requires further studies of fracture 
incidence in breast cancer patients with and without tamoxifen with adjustments 
for potential confounding factors. 
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There are several limitations in the studies included in this review. Small 
sample size is a prevalent problem. More than half had a study population of less 
than 100 people. Since BMD change is often subtle with the known highest 
increase less then 8% (Figure 2), these studies may have failed to detect a 
difference due to inadequate statistical power. The complexities of disease 
features and treatments in these patients also add to the difficulties of 
determining the effect of tamoxifen on bone health. Few studies included 
hormone receptor information and many patients had mixed treatment at a given 
time period of disease. This led to problematic variation in study groups. The 
quality assessment demonstrated that most of the studies included in this review 
scored poorly with an average below the 50% of maximal score of 32. Although 
many studies indicated that the BMD change resulting from tamoxifen treatment 
for both hip and spinal bones was around 4%, the limited studies scoring above 
50% of maximal score found a lower increase of 2% (Figure 3). These studies 
may better reflect the true effect of tamoxifen on BMD. Finally, it is important to 
note that no studies were found that assessed BMD change in relationship to 
fracture incidence in patients with tamoxifen treatment.  
Tamoxifen has been the first choice for hormonal therapy for women with 
breast cancer. Other agents such as toremiphene are not widely adopted in 
clinical practice because of their relatively lower efficacy and/or inadequate 
information on benefit and safety profile. However recently, third-generation 
aromatase inhibitors have replaced tamoxifen in guideline recommendations for 
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breast cancer treatment of postmenopausal women.21 One important implication 
of this review is that tamoxifen may still be a valuable choice for postmenopausal 
women with breast cancer who also suffer from osteoporosis. However, because 
of the discrepancy between the BMD change and fracture incidence in the 
studies in this review, recommendations for clinical practice are not clear. Finally, 
it must be pointed out that the protective effect of tamoxifen on bone may have 
extra benefit for some breast cancer patients, but it cannot and should not 
replace osteoporosis prevention and anti-osteoporotic therapy for breast cancer 
patients at high risk of or with osteoporosis. BMD screening for such patients 
during tamoxifen treatment is necessary and a clinical recommendation for 
starting anti-osteoporotic therapy can be decided at an appropriate time.  
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Table 1. Summary of original studies of effect of tamoxifen alone on BMD 
 
BMD 
Hip Spine Arm Total body 
 
Author, 
year 
 
Sample 
size 
 
Study 
design 
 
Age (range, 
average) 
 
 
Stage of breast 
cancer  
 
Tamoxifen 
therapy 
 
Dose 
(mg/d) 
 
Method of 
BMD measure 
 
Control 
Tam Control Tam Control Tam Control Tam Control 
 
Quality 
score 
Barni  
1996 
40 Cohort 52-79 T1, T2, T4 1 yr 20 PA Baseline     0% (BMD 
change) 
   11 
Cameron 
2002 
140 RCT 58.1 Axillary-node-
negative  
2 yrs 20 PA Baseline   Β=0.03**      13 
Crandall 
2004 
66 in 
280 
Cohort Post-
menopausal 
Breast Cancer 
Survivor 
N/a N/a DXA Age and ethnicity-
matched control 
0.073(Z-score) 0.146(Z-score) 0.076(Z-score) 0.235(Z-score)   0.275(Z-score) 0.544(Z-score) 9 
Eastell  
2006 
308 Cohort 56.5-70.3/63.9 Invasive primary 
breast cancer 
2 yrs 20 DXA Baseline +1.2%  +2.2%      19 
Fornander 
1990 
75 RCT 52-70 Breast Cancer 
Survivor 
2-5 yrs 40 PA No Adjuvant     Proximal 0.99 
(g/cm2, 2yr) 
1.06(g/cm2, 5yrs) 
Distal  
0.70(g/cm2, 2yrs) 
0.78(g/cm2, 5yrs) 
Proximal 1.05 
(g/cm2) 
 
Distal  
0.74 (g/cm2) 
  17 
Fornander 
1994 
13 Cohort 51-75/63 Stage I, II 1 yr 40 PA Baseline     0% (BMD 
change) 
   7 
Kalef-Ezra 
1992 
76 Cohort 41-65/53 No skeletal 
metastases 
12-45 mos 20 PA Healthy Control     95.2%(12-
20mos) 
102.4%(21-
45mos) 
100%   8 
Kalef-Ezra 
1996 
33 in 
222 
Cohort Post-
menopausal 
No skeletal 
metastases 
30 mos 20 PA Healthy Control     -1.0% -0.8%   13 
Kristensen 
1994 
50 RCT Post-
menopausal 
Axillary-node-
negative 
2 yrs 30 PA No Adjuvant   +2.5%** -5% -2.5%* -6.5%   15 
Leslie  
1995 
31 in 86 Cohort 62.0 Stage II 33.9 mos 20 PA Baseline -0.1%  -0.1%      10 
Love  
1992 
140 RCT 58 Axillary-node-
egative 
2 yrs  PA Placebo   +0.61%/yr* -1.00%/yr -0.88%/yr -1.29%/yr   23 
Love  
1994 
62 in 
140 
RCT 58.2 Axillary-node-
negative 
5 yrs 20 PA Placebo   +0.8% -0.7%     21 
Marttunen 
1998  
16 in 30 RCT 61.5 Stage II 1 yr 20 DXA Baseline +1%(femoral 
neck) 
+5%*(Ward’s 
triagle) 
 +2%*      14 
Marttunen 
1999 
15 in 30 RCT 61.5  Stage II 1 yr 20 DXA Baseline +0.7% (femoral 
neck) 
+1.2(Trochanteric 
region) 
+2.8%(Ward’s 
triangle) 
 +0.4%      14 
Neal  
1993 
38 Cohort 45-84 Non distant 
metastases 
>=5 yrs 20/40 DXA Healthy control 0.934(g/cm2) 0.877(g/cm2) 1.081(g/cm2) 1.065(g/cm2)   1.078(g/cm2) 1.057(g/cm2) 11 
Resch  
1998 
111 Cross 
sectional/ 
Cohort 
Late post-
menopausal 
Stage I, II 5 yrs 20 QCT No Adjuvant   -0.8*(Z-score, 
cross sectional) 
+1.9%*(cohort) 
-1.5(Z-score, 
cross sectional) 
-4.8% (cohort) 
    8 
Rodriguez 
2005 
22 in 
168 
Cohort Post-
menopausal  
Stage I, II, III 1 yr  DXA Baseline 0.737(g/cm2, 
femoral neck) 
0.663*(g g/cm2, 
trochanter) 
1.032(g/cm2, 
intertrochanter) 
0.553(g/cm2, 
Ward’s triangle) 
0.874(g/cm2, 
total hip) 
0.725(g/cm2, 
femoral neck) 
0.644(g/cm2, 
trochanter) 
1.016(g/cm2, 
intertrochanter) 
0.558(g/cm2, 
Ward’s triangle) 
0.860(g/cm2, 
total hip) 
0.927(g/cm2) 0.898(g/cm2)     12 
Ryan  
1991 
8 Cohort 44-75 No skeletal 
metastases 
1 yr 20 PA Baseline   +3.6% **(6 mos) 
+4.3% **(12 mos)
     9 
Tiitinen 
2004 
36 in 70 RCT 60.4 Stage II, III 3 yrs 20 DXA Baseline 0.814(g/cm2, 
femoral neck) 
0.713(g/cm2, 
trochanter) 
0.643(g/cm2, 
Ward’s triangle) 
0.822(g/cm2, 
femoral neck) 
0.717(g/cm2, 
trochanter) 
0.618(g/cm2, 
Ward’s triangle) 
0.945(g/cm2) 0.964(g/cm2)     15 
Turken  
1989 
20 Cohort 49-72/60.7 Non distant 
metastases 
1 yr 20 PA Healthy Control   +0.024(g/cm2,  
6 mos) 
+0.022(g/cm2,  
12 mos) 
-0.012(g/cm2,  
6 mos) 
-0.024*(g/cm2,  
12 mos) 
    7 
Ward  
1993 
36 Cohort Post-
menopausal 
Stage I II 1 yr 20 DXA Healthy control +1.4%* -1.8% +0.09%* -2.3%     10 
Yoneda 
2002 
21 Cohort 62.5 Stage I, II 1 yr 20 DXA Baseline ±   +3.3%**(6 mos) 
+2.7%**(12mos)
     13 
2 2 2 2Zidan 
2004 
44 Cohort 47-75/63.4 T1-T2N0M0 12 mos 20 DXA Baseline 0.85(g/cm ) 0.84(g/cm ) 1.09(g/cm ) 1.06(g/cm )     15 
+ Increase, - Decrease, ± No change, *p<0.05, **p<0.01. 
PA= Photon absorptiometry, DXA=Dual energy X-ray absorptiometry, QCT=Quantitative computed tomography. 
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Breast Cancer AND Tamoxifen 
OR Bone OR Osteoprosis OR
Bone Density OR Bone Fracture 
(limited to  Human+Female
+Age>=45+English)
(N=307 articles)
Original studies
(N=261)
Studies relevant to 
tamoxifen with
appropriate bone 
health information
and control
(N=32)
Available studies 
in post menopausal 
women with 
breast cancer
(N=25)
Studies included
(N=26)
Reviews
(N=46)
Non-tamoxifen studies;
Preventive setting;
No BMD/Fracture data;
No self/healthy/
non-tamoxifen control
(N=229)
Studies in healthy
or premenopausal
Women;
Studies not
retrievable
(N=7)
Reference search
(N=1)
 
 
Figure 1 Literature search strategy 
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*Self control uses patients’ baseline BMD values.             
†Matched control is either patients without tamoxifen therapy 
or healthy subjects.  
 
Figure 2  Effect of tamoxifen on BMD at different skeletal sites 
 
 
 
24 
 
 
 
 
 
 
 
 
 
 
 
-4
-2
0
2
4
6
8
10
0 5 10 15 20 25
Quality score
BM
D
 c
ha
ng
e 
(%
)
Hip Spine Wrist
 
 
 
 
 
Figure 3  Relationship between the quality of studies and findings of BMD change 
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1.4 Tamoxifen and CHD 
 
Coronary heart disease (CHD) in women has a clear association with 
estrogen. It has been perceived that postmenopausal women are at a similar 
risk of CHD as their male counterparts mainly because of the decreased level 
of estrogen resulting from menopause.66 Hormone replacement therapy has 
been hypothesized to be a powerful tool to lower cardiovascular incidence in 
postmenopausal women. However, despite the positive evidence from many 
observational studies,67-71 some randomized trials,72, 73 especially the 
Women's Health Initiative study,74 failed to support the hypothesis. In the 
search for alternatives to hormone replacement therapy, SERMs emerge as a 
promising candidate. Due to the fact that SERMs are not steroids, they may 
avoid a summation of the effects of estrogen while mimicing the estrogenic 
action on coronary arteries. In postmenopausal women with breast cancer, 
tamoxifen has been proven to lower serum lipid levels.45, 75-77 More directly, 
tamoxifen has demonstrated an association with a reduced risk of CHD in 
several clinical trials.78-80 Recently, in a cohort of 11,045 women with breast 
cancer, Geiger et al showed no change in the  risk of myocardial infarction (MI) 
in patients treated with tamoxifen.81 In a nested, matched, case-control study 
among 7263 women, Brandbury and his colleagues demonstrated that five 
years of tamoxifen therapy reduced the risk of acute MI or angina (adjusted 
OR, 0.4; 95% CI, 0.2–0.7) compared to patients without tamoxifen.82 Taken 
together, the current evidence from both clinical trials and observational 
studies appear to suggest that tamoxifen may reduce the risk of CHD in 
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women with breast cancer. Future cohort studies with a focus specifically on 
postmenopausal breast cancer women will add valuable information about 
CHD in this high-risk population.  
 
 
 
1.5 Summary 
 
 
  Breast cancer is one of the leading threats to women’s health. 
Tamoxifen, the most successful SERM agent, has been used in hormonal 
therapy for three decades. Along with its therapeutic effect on breast 
cancer, tamoxifen also demonstrates potential benefits for bone and heart 
health. However, many questions associated with the beneficial effects 
remain to be answered: 1). Why have the few available studies failed to 
show a protection from  tamoxifen on fractures while the majority of 
research demonstrated an increased BMD resulting from tamoxifen? How 
well does BMD predict the risk of fractures in patients with breast cancer? 
2). Does tamoxifen protect breast cancer patients from fractures? 3). 
Whether and to what extent does tamoxifen reduce the risk of CHD?  
 
 As hormone replacement therapy for aging-associated female health 
problems has become controversial after the WHI trial, it is essential to 
clarify the role of SERMs and tamoxifen in particular on the prevention or 
treatment of osteoporosis and CHD. The proposed study is an attempt to 
enrich the knowledge on this issue and potentially generate valuable 
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information for both breast cancer treatment and the health of 
postmenopausal women.  
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CHAPTER II 
 
Tamoxifen use and the risk of fractures in postmenopausal women with 
breast cancer 
2.1 ABSTRACT 
 
Adjuvant tamoxifen therapy in postmenopausal women with breast 
cancer has been repeatedly demonstrated to preserve bone mineral density. 
However, whether it prevents bone fractures is not clear. In fact, the few 
available studies exploring the association of tamoxifen use and fractures 
indicated an increased risk of fractures. We conducted a retrospective cohort 
study on the association of tamoxifen use and risk of fractures in an insured 
population of patients with breast cancer aged 55 or older by comparing those 
under tamoxifen therapy to patients who did not receive the treatment. Our 
results showed that the association between tamoxifen use and fracture risk 
varied at different skeletal sites. Although the relationship of tamoxifen and 
fractures in the spine (HR=0.40, 95% CI: 0.09-1.85), wrist (HR=2.49, 95% CI: 
0.88-7.06), and total body (HR=0.87, 95% CI: 0.49-1.55) was inconclusive, 
tamoxifen was associated with an apparent reduction of the risk of hip fracture 
(HR=0.41, 95% CI: 0.17-1.03, p=0.0565). Importantly, the pattern of observed 
association of tamoxifen with fractures in postmenopausal women with breast 
cancer is consistent with its widely reported preserving effect on bone mineral 
density. Further study is necessary to evaluate the precise magnitude of 
benefit conferred by tamoxifen on bone fractures. 
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2.2 INTRODUCTION 
 
Bone health is a concern in the treatment of breast cancer. 
Postmenopausal women who represent the largest portion of elderly women 
with breast cancer may be at higher risk of fractures through a combination of 
risk factors including female gender, older age, and hormonal change. 
Increased bone loss in these postmenopausal breast cancer patients may 
also result from chemotherapy [1] and adjuvant therapy agents such as 
aromatase inhibitors [2, 3]. Thus, in order to improve the overall survivorship 
of this specific patient population, the impact of cancer treatment on bone 
health in addition to its anti-tumor effect deserves consideration. 
 
Adjuvant tamoxifen therapy is, theoretically, an ideal treatment for 
postmenopausal women with breast cancer who have a fracture concern. Due 
to the fact that tamoxifen is a SERM (Selective Estrogen Receptor Modulator) 
which suppresses tumor cells in the breast but has an estrogenic effect in 
other tissues such as bone [4-8], it has been speculated to mimic the estrogen 
protection on bone. Indeed, studies investigating the association of tamoxifen 
and bone mineral density (BMD) in postmenopausal women with breast 
cancer have repeatedly demonstrated increased BMD in the hip and spine, 
although a similar association was not seen in the wrist [9]. In addition, when 
combined with chemotherapy, tamoxifen has been found to partially prevent 
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or reverse the bone loss resulting from chemotherapy [10, 11]. Studies also 
found that patients with a history of hormone replacement therapy 
experienced bone loss during tamoxifen therapy compared to an increased 
BMD seen in those without such history [12, 13]. Overall, the evidence 
suggests the benefit associated with tamoxifen on BMD appear to be 
consistent with the estrogenic effect of tamoxifen. 
 
Few studies investigating the association of tamoxifen and fractures, 
the ultimate outcome of deteriorated bone health, are available. Despite the 
widely reported apparent beneficial effect of tamoxifen on BMD in 
postmenopausal women with breast cancer, whether it prevents bone 
fractures is not clear. In fact, the only two original studies of tamoxifen on 
bone fractures in postmenopausal breast cancer patients who received 
tamoxifen therapy found no protective effect but an increase in spine or hip 
fracture incidence [14, 15] while a cross-study comparison based on data 
from three different studies failed to find a difference in overall fracture 
incidence [16]. The unexpected increase of fracture incidence in those studies 
requires further investigation.  
 
In the present study, we conducted a retrospective cohort study on the 
assocaiton of tamoxifen use and risk of fractures in an insured patient 
population aged 55 or older. By comparing breast cancer patients taking 
tamoxifen to those who did not receive the treatment, we investigated the 
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relationship between tamoxifen use and the risk of fractures in a setting of 
community-based treatment. As adjuvant hormonal therapy shifts from 
tamoxifen to aromatase inhibitors (AIs), our study provides information to 
clarify the discrepancy between BMD and fractures and to evaluate the added 
value of tamoxifen use in postmenopausal women with breast cancer due to 
its potential benefit on bone health.  
 
2.3 METHODS 
Study population 
 
The data we used for this study is from four large integrated health 
care delivery systems (HealthPartners, Minneapolis/St Paul, MN; Fallon Clinic, 
Worcester, MA; Kaiser Permanente Northern California, San 
Francisco/Sacramento, CA; and Henry Ford Health System, Detroit, MI) that 
participate in the Cancer Research Network (CRN) which consists of 14 
health care delivery systems [17, 18]. Postmenopausal patients (aged 55 or 
older) with newly diagnosed breast cancer between January 1, 1996 and 
December 31, 1997 were included in this study. These patients were followed 
for a maximum of seven years to the date of death, or disenrollment, or the 
last day of the follow-up, (December 31, 2002) with a follow-up rate of 85.8%. 
This study was approved by the institutional review boards of all sites. 
 
Identification of breast cancer cases and study parameters 
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 Breast cancer patients were identified through health system 
registries at two sites (Henry Ford and Kaiser Permanente) with tumor 
registries. At two sites without such access (HealthPartners, Fallon Clinic), 
automated data bases with medical record confirmation were used.  In-situ 
and invasive cases were included and tumor stage was categorized as 0 
(in-situ), I, II, III, or other (IV or unknown) according to the criterion of the 
American Joint Commission on Cancer (AJCC).  All breast cancer patients 
with AJCC stage 2 or greater plus an age-stratified random sample of 
patients with stage 1 or less as well as all patients at the two sites without 
tumor registries were selected. At the largest site (Kaiser Permanente), 
one-fifth of patients with stage 0 or 1 breast cancer were sampled. In total, 
897 women with breast cancer were included. All cases were confirmed 
through medical record reviews by trained abstractors [19].  
  
 In addition to the breast cancer information, data including 
demographics (age and race), tumor stage, cancer treatments (surgery, 
chemotherapy, and radiotherapy), comorbidities, plus tamoxifen use were 
collected by the chart abstractors supplemented by electronic pharmacy 
data. A modified Charlson comorbidity score [20] for the two years prior to 
diagnosis of breast cancer was derived from the abstracted information, 
weighted as originally developed, and categorized as 0, 1, 2, or 3 and 
above.  
 
45 
 
 The outcome parameter, fracture, was extracted from administrative, 
electronic medical utilization data that included inpatient and outpatient 
diagnoses and procedures. Osteoporotic fractures were identified using 
the following criterion   [21]: at least one of ICD-9-CM diagnosis codes 
(805.xx-vertebral, 807.0x or 807.1x-rib, 813.xx or 814.xx-wrist, and 820.xx-
hip) or one of The Current Procedural Terminology (CPT) procedure codes 
(7607x and 7835x) from inpatient data, or at least two of ICD-9-CM 
diagnosis codes for the same fracture on different dates or one diagnosis 
code plus one CPT procedure code from outpatient data. Patients with a 
fracture during the two years prior to diagnosis of breast cancer were 
excluded from this analysis. For BMD testing status, the ICD-9-CM 
diagnosis code 88.98 and CPT codes 76070, 76071, 76075, 76076, 76078, 
76499, 76977, 76999, 78350, 78351 were used for the data extraction [22, 
23]. Finally, information about anti-osteoporosis treatment was obtained 
from pharmacy data using NDC (National Drug Code) codes for raloxifene, 
calcitonin, alendronate, and risedronate. Anti-osteoporotic pharmacy data 
were not collected at one study site (Kaiser Permanente North California). 
 
Statistical analysis 
 
 Outliers with potential impact on study results were checked and all 
patients were kept in the data analyses because the exclusion of outliers 
did not change the association of tamoxifen use with fractures. Age was 
categorized into six groups from 55-59 to 80+ by five year intervals. All 
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other characteristics of patients included in the study are either 
dichotomous or categorical variables. Chi-square tests were used for the 
comparison of characteristics between patients treated with tamoxifen and 
those who did not receive such treatment.  
 
 To compare of the incidence of fractures over time between 
patients who did and did not receive tamoxifen, we used the Kaplan-Meier 
survival method. Both overall and site specific fractures in the spine, hip, 
and wrist of patients were compared by tamoxifen use status. The 
association between tamoxifen use and risk of first fracture at a specific 
skeletal site (spine, hip, and wrist) as well all sites combined (total body) 
was examined using Cox proportional hazards regression, providing 
hazard ratio (HR) estimates and 95% confidence intervals (95% CI), with a 
series of adjustments for potential confounders. Tamoxifen use was 
treated as a time-dependent covariate in regression models. The time prior 
to the beginning of tamoxifen therapy was considered as non-tamoxifen 
use status. Because of the limited number of fractures at individual 
skeletal sites and the similarity of fracture incidence between the time 
periods of during and after tamoxifen therapy (data not shown), we did not 
further differentiate these two stages of tamoxifen use in the data analyses. 
For comparison, we also tested tamoxifen use as a dichotomous variable 
as well as fitting Poisson models (using generalized estimating equations) 
and obtained similar results (data not shown). Although Charlson 
comobidity score, BMD testing status, and anti-osteoporotic therapy are 
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potential predictors of fractures, these factors were not associated with 
tamoxifen use (Table 1), and the inclusion of these factors in the model did 
not significantly affect the results (data not shown). In addition, the 
hormone receptor status (ER/PR) was not used in the regression analyses 
because the data are only available at two out of four study sites, and the 
pattern of the association of tamoxifen and fractures at different skeletal 
sites observed from the analyses restricted to the two sites with the ER/PR 
information did not differ from the one using the whole dataset. Given the 
clinical and epidemiological significance as well as the preliminary 
analyses, we included age, race, surgery status, and cancer stage in the 
final model.  Statistical significance was defined at the α=0.05 level. 
Analyses were performed using SAS software, version 9.1 (SAS Institute, 
Inc., Cary, NC). 
 
2.4  RESULTS 
 
The baseline characteristics of patients are presented in Table 1. After 
the exclusion of patients with a fracture prior to the diagnosis of breast cancer, 
there are 866 women with breast cancer included in this study. Of these, more 
than half (487) received tamoxifen therapy. Age distribution in each age group 
is similar between tamoxifen users and non-users. However, there is a higher 
percent of black patients in the non-tamoxifen group (11.87% vs 9.65%). 
Tamoxifen users were generally hormone-receptor-positive (83.81%) while far 
fewer non-tamoxifen users had positive hormone receptor status (40.98%). As 
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expected, few patients with in-situ breast cancer received tamoxifen (2.26% 
vs 29.29%). A significantly higher percent of non-tamoxifen users had breast-
conserving surgery (BCS) than those taking tamoxifen (60.16% vs 49.28%, 
P=0.0016). For other major cancer treatments (chemotherapy and 
radiotherapy), no difference is seen between the two patient groups. 
Comorbidity conditions are similar in patients with or without tamoxifen 
therapy although a slightly higher percent of patients in the category of score 
0 of Charlson index are found in the tamoxifen user group (66.53% vs 62.01%, 
P=0.1961). In terms of osteoporosis associated medical utilization, an almost 
identical percent of patients in both groups received BMD testing (25.67% vs 
25.07%) as well as anti-osteoporotic therapy (12.77% vs 11.61%), suggesting 
a similar perceived fracture risk at baseline.  
 
 Fractures at three common fracture sites (spine, hip, and wrist) and 
total body are visualized using Kaplan-Meier survival functions in Figure 1. 
A reduced fracture event trend can be observed in the spine over time, 
and this trend is more noticeable in the hip. However, an increase of 
fracture events is seen in the wrist, while the combined fracture events of 
all skeletal sites do not differ between patients with and without tamoxifen 
therapy at any time in the follow-up period. Due to the fact that fracture 
events are low at all sites (ranging from 1% to 7%), the differences by 
tamoxifen use status at the individual skeletal sites are small, and none 
are statistically significant at the p<0.05 level. 
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 Table 2 presents the risk of fractures for patients with and without 
tamoxifen therapy. Fracture cases identified at each skeletal site are 
relatively few, especially in the spine, where only 11 factures were found. 
The total number of patients with incident fractures after the diagnosis of 
breast cancer is 59, with some patients having fracture events at multiple 
skeletal sites on a given date. Compared to non-tamoxifen users, the 
fracture incidence over the period of follow-up time is lower among the 
tamoxifen users in the spine (1.64 vs 3.89/1,000 person years) and hip 
(4.13 vs 7.35/1,000 person years). A higher incidence of fracture is seen in 
the wrist among the patients with tamoxifen therapy. Results of the Cox 
proportional hazards regression analyses find that tamoxifen users have a 
60% (95% CI: 0.10-1.55) reduction in risk of fracture in the spine, 44% 
(95% CI: 0.24-1.30) in the hip, and no change for total body before model 
adjustment (Unadjusted Model), but a 121% (95% CI: 0.89-5.45) increase 
in the wrist. The addition of age and race, two common confounders, has 
little impact on the estimates of risk (Model 2 and Model 3). Similarly, 
surgery status does not dramatically affect risk estimates (Model 4). 
However, the stage of cancer has a strong effect on the prediction of the 
fracture risk by tamoxifen use status. After the inclusion of this factor in the 
final model, the risk of fracture (HR) was changed from 0.56  (95% CI: 
0.24-1.30) to 0.41 (95% CI: 0.17-1.03) in the hip, from 2.21(95% CI: 0.89-
5.45) to 2.49 (95% CI: 0.88-7.06) in wrist, and from 0.99 (95% CI: 0.58-
1.68) to 0.87 (95% CI: 0.49-1.55) in total body. The hazard ratios in the 
final adjusted models are not statistically significant except for hip fractures 
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where the reduction of fracture risk is of borderline statistical significance 
(HR: 0.41; 95% CI: 0.17-1.03; P=0.0565).  
 
 
2.5  DISCUSSION 
 
 Compelling evidence from previous studies demonstrated that 
tamoxifen preserved BMD in postmenopausal patients with breast cancer. 
This preservation is evident in the hip and spine but not detectable in the wrist 
[9].  However, opposite to common speculation, observations documented in 
the few available studies regarding the association of tamoxifen and fractures 
showed an unexpected increase of the risk of fractures in patients taking 
tamoxifen. One study conducted as a randomized controlled trial of 1716 
breast cancer patients with an average age of 54 years for one year found a 
significant increase of spinal fracture (OR=2.12, 95% CI: 1.12-4.01) in those 
taking tamoxifen [15]. Furthermore, a nearly five times higher risk of hip 
fracture among patients taking tamoxifen (OR=4.7, 95% CI: 2.3-9.9) was 
observed in a two to three year cohort study in which 79% of 352 breast 
cancer patients received either tamoxifen alone or in combination with 
chemotherapy (14). Although these studies have many strengths, their 
findings could be biased by several factors such as the complexity of the 
patient population, the suitability of the controls, the length of tamoxifen use, 
the accuracy of identification of fractures, and the short follow-up.    
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 In the present study, we investigated the association of tamoxifen 
and fractures in three common skeletal fracture sites (spine, hip, and wrist) 
plus combined sites (total body) in postmenopausal women with breast 
cancer in an insured population. Our results showed that the association of 
tamoxifen and fractures varied at different skeletal sites. While the 
association of tamoxifen and the risk of fractures in the spine (HR=0.40, 
95% CI: 0.09-1.85), wrist (HR=2.49, 95% CI: 0.88-7.06), and total body 
(HR=0.87, 95% CI: 0.49-1.55) was inconclusive, an apparent reduction of 
fracture risk was found in the hip (HR=0.41, 95% CI: 0.17-1.03) with 
borderline statistical significance (p=0.0565). The effect estimates, 
especially in the spine where subtle fractures are likely to be under-
diagnosed, are imprecise. However, the pattern of the associations of 
tamoxifen and various fracture sites found in this study was similar to its 
preserving effect on BMD in a recent systematic review of 27 studies [9] 
which demonstrated a site-specific preservation on the spine and hip but 
not the wrist. In addition, the reduced fracture risk seen in this study was 
consistent with the findings reported in a breast cancer prevention setting 
using tamoxifen [24], further supporting the possibility of a benefit 
associated with tamoxifen on fractures. 
 
 Our study is strengthened by several factors. The study population 
we used is insured and received care in integrated health care systems. 
This study setting ensures a diverse patient population with equal health 
service access so that treatment decisions such as tamoxifen use are 
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likely to be based on medical needs. The collection of data in this study, 
including breast cancer diagnosis, medical utilization, and follow-up is 
complete. The use of medical record reviews by trained medical 
abstractors further reduces selection and information biases. In fact, the 
majority of patients had at least two years of tamoxifen therapy (data not 
shown) enhancing the chance of detection of changed risk of fractures 
resulting from longer tamoxifen use. The relatively long follow-up period of 
a maximum of seven years enables us to accumulate more information on 
fracture, so that this relatively rare medical outcome can be studied.   
 
 Although this study is carefully designed to overcome or circumvent 
common problems, there are some weaknesses that could affect the study 
results. Despite an identified trend of reduced risk of fracture in patients under 
tamoxifen therapy, the findings were not statistically significant except for a 
borderline significant change in hip fractures. One explanation is the limited 
sample size. A power calculation shows that in order to detect a relative risk 
(HR) of 0.41 in the hip found in this study at the β=0.8 level in this patient 
population, a sample size of 1,588 is required. Our study sample (N=897) 
does not meet that requirement. Thus, we were only able to detect the trend 
but not statistical significance for spine and wrist fractures as well as total 
fractures. However, the study population is large enough to confirm a 4.7 
times risk of spine fracture [15] for which only 175 patients would be needed. 
Since we did not observe an increase but a decrease of the risk of hip fracture, 
the large increased risk of hip fracture observed in the previous study is more 
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likely the result of other factors than tamoxifen, and the possibility of a 
potential benefit associated with tamoxifen on fractures in the hip still holds. 
Given the magnitude of findings (no reduction to 65% reduction ) from major 
clinical trials including the MORE trial (the Multiple Outcomes of Raloxifene 
Evaluation) [25] which was conducted in 7705 women with postmenopausal 
osteoporosis treated with raloxifene, a SERM for the treatment of 
osteoporosis, and the trials of bisphosphonates such as VERT (the Vertebral 
Efficacy with Risedronate Therapy) [26, 27], HIP (Hip Intervention Program) 
[28], and FIT (the Fracture Intervention Trial) [29, 30], it is understandable that 
we found a trend of rather than a large and statistically significant reduction of 
the risk of fractures associated with tamoxifen, a weaker protection of bone 
than these pharmacologic agents for osteoporosis. Other limitations of the 
study include reliance on administrative data for the identification of fractures. 
Fractures in some patients, especially those who have numerous 
comorbidities might not be documented or documented as a secondary 
diagnosis. The low rate of spine fractures [16] reinforces the potential 
underestimation of fractures identified in this study. The lack of information 
about some risk factors of osteoporosis associated fractures such as body 
mass index, BMD measures, T-score, smoking status, hormone replacement 
therapy, the history of fractures [31] as well as aromatase inhibitor use may 
leave uncontrolled confounding. An additional limitation is that although all 
patients included in this study are postmenopausal women, a population with 
high risk of osteoporosis, one third of them who are 65 or younger. We could 
have more power to clarify the association of tamoxifen and fracture if these 
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patients were older. The inconclusive findings observed in this study could be 
clarified if we had a similar size but older patient population. 
 
 Tamoxifen has been the first-line adjuvant hormonal therapy in 
postmenopausal women with breast cancer for three decades and is 
currently being replaced by third-generation aromatase inhibitors (AIs) [32]. 
Although AIs have been proven to be equal to or better than tamoxifen as 
treatment for hormone-receptor-positive breast cancer [33], the fact that 
they increase the risk of fractures [2, 3] restricts their application in 
patients who are also at high risk of osteoporosis. Tamoxifen appears an 
ideal choice in this situation because of its preservation of BMD. However, 
since initial studies found an unexpected increase of fracture risk in 
patients under tamoxifen therapy, no subsequent studies have been 
conducted to answer the question. Since Als, the current recommended 
adjuvant hormonal therapy, increase the risk of fractures, the clarification 
of tamoxifen use on fracture risk in postmenopausal women with breast 
cancer is important. Our study suggests a reduced risk of fractures in the 
hip and possibly in the spine. While we were preparing this manuscript, a 
case control study set in a large administrative database without full 
information on breast cancer status demonstrated a similar protection of 
tamoxifen on fractures in a predominantly non-breast cancer population 
(97%) [34]. Future studies in different settings are necessary to elucidate 
the precise magnitude of the benefit associated with tamoxifen on 
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fractures and help to clarify confusion resulting from the increased fracture 
risk associated with tamoxifen therapy in previous studies.  
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Table 1. Characteristics of women with breast cancer by tamoxifen-use status (%) 
 Tamoxifen user 
(N=487) 
Non-tamoxifen user 
(N=379) 
P value 
Age  
      55-59 
      60-64 
      65-69 
      70-74 
      75-79 
      80+ 
 
18.89 
16.84 
17.25 
17.45 
18.89 
10.68 
 
20.58 
15.30 
16.62 
17.94 
16.89 
12.66 
0.9583 
Race 
      White 
      Hispanic 
      Black 
      Asian/Pacific 
      Unknown 
 
81.93 
1.85 
9.65 
4.11 
2.46 
 
81.27 
1.32 
11.87 
3.17 
2.37 
0.9131 
Hormone receptor status 
(ER/PR)† 
      Positive 
      Negative 
      Unknown 
 
(n=247) 
83.81 
4.45 
11.74 
 
(n=205) 
40.98 
16.10 
42.93 
<0.0001 
Cancer Stage 
      0 
      I 
      II 
      III 
      Other 
 
2.26 
49.90 
32.65 
8.83 
6.37 
 
29.29 
45.12 
16.36 
2.90 
6.33 
<0.0001 
Surgery 
      None 
      BCS 
      Mastectomy 
 
5.13 
49.28 
45.59 
 
3.43 
60.16 
36.41 
0.0016 
Chemotherapy 
      Yes 
      No 
 
20.53 
79.47 
 
16.62 
83.38 
0.1443 
Radiotherapy 
      Yes 
      No 
 
46.82 
53.18 
 
49.09 
50.92 
0.5093 
Charlson score 
      0 
      1 
      2 
      >=3 
 
66.53 
19.51 
6.98 
6.98 
 
62.01 
21.11 
9.23 
7.65 
0.1961 
BMD testing 
      Yes 
      No 
 
25.67 
74.33 
 
25.07 
74.93 
0.8403 
Anti_osteoporotic  
therapy†† 
      Yes 
      No 
 
(n=321) 
12.77 
87.23 
 
(n=267) 
11.61 
88.39 
0.6689 
†   Data not available at two HMO sites (Fallon Clinic, MA and Henry Ford Health, MI).†† Data not 
available at one HMO site (Kaiser Permanente, CA). 
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  Figure 1.  Survival possibility from fractures at different skeletal sites in patients by tamoxifen use status 
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 Table 2. Comparison of fractures in breast cancer patients with versus without tamoxifen therapy 
Fracture Incidence (/1000 
pys) 
HR (95% CI) Fracture 
site 
Number 
of  
Cases 
 
Tamoxifen 
user 
Non-tamoxifen
user  
Unadjusted  
Model 
Model 2 Model 3 Model 4 Full Model 
Spine 11 1.64 3.89 0.40 (0.10, 
1.55) 
0.40 (0.10, 
1.55) 
0.40 (0.10, 
1.57) 
0.40 (0.10, 
1.58) 
0.40 (0.09, 
1.85) 
Hip 23 4.13 7.35 0.56 (0.24, 
1.30) 
0.55 (0.23, 
1.28) 
0.54 (0.22, 
1.26) 
0.53 (0.22, 
1.26) 
0.41 (0.17, 
1.03) 
Wrist 24 6.65 4.45 2.21 (0.89, 
5.45) 
2.25 (0.91, 
5.58) 
2.22 (0.89, 
5.53) 
2.27 (0.91, 
5.66) 
2.49 (0.88, 
7.06) 
Total Body 59 13.04 16.03 0.99 (0.58, 
1.68) 
0.99 (0.58, 
1.67) 
0.96 (0.57, 
1.63) 
0.98 (0.57, 
1.67) 
0.87 (0.49, 
1.55) 
Unadjusted Model: Tamoxifen only (reference: non-tamoxifen user) 
Model 2: age adjusted 
Model 3: age+race adjusted 
Model 4: age+race+surgery adjusted 
Full model: Tamoxifen+age+race+surgery+cancer_stage 
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CHAPTER III 
 
Association between bone mineral density and fractures in elderly women 
with breast cancer 
 
 
3.1 Abstract 
 
 
Bone mineral density (BMD) is the gold standard for the diagnosis of 
osteoporosis. However, the association of osteoporotic fractures and BMD is not 
fully understood. BMD has been linked with different risks of fractures between 
sexes, races, and at different skeletal sites. In addition, studies have reported a 
null association of BMD and fractures among patients treated with anti-
osteoporotics and a paradoxical discrepancy between BMD and fractures in 
breast cancer women under tamoxifen therapy. In the present study, we 
investigated the association of BMD and fractures among elderly women with 
breast cancer who participated in the Study of Osteoporotic Fractures in 
comparison to women without breast cancer. Our results demonstrate that 
women with breast cancer have a higher BMD value and lower risk of fractures. 
Compared with the consistent association of BMD and fractures in those without 
breast cancer, the association between BMD and fractures in women with breast 
cancer varies by different skeletal sites, and type of BMD. Non-specific BMD was 
not associated with hip fracture (HR=1.12; 95% CI: 0.78, 1.59). Site-specific BMD 
was more likely linked with hip fracture (HR=1.43, 95% CI: 0.99, 2.08) while 
change in BMD did not predict hip fracture (HR=1.05; 95% CI: 0.63, 1.72). The 
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association of spine morphometric fracture with either non-specific or spine-
specific BMD was similar (OR=1.40; 95% CI: 1.04, 1.90; OR=1.35, 95% CI: 0.99, 
1.85, respectively). In conclusion, the association of BMD and fracture in elderly 
women with breast cancer is weak. Thus, these finding suggest that BMD may 
have reduced value in predicting and monitoring the risk of fractures in this 
patient population. Alternative risk factors that are unique or better predictors of 
fractures in women with breast cancer need to be identified.  
 
Key words: Bone mineral density, Fracture, Osteoporosis, Breast cancer 
 
3.2 Introduction 
 
Osteoporosis is one of the leading threats to women’s health. 
Postmenopausal women are at an increased risk of this disease because of 
aging-associated progressive bone loss. While bone loss itself may not have 
severe clinical symptoms, fracture, the ultimate outcome of osteoporosis, causes 
tremendous suffering and life loss in patients with this disease, and the social 
and economical burdens are overwhelming 1-4. Understanding the likelihood of a 
fracture in patients with osteoporosis is an important element of osteoporosis 
management. A preventive strategy and necessary treatment based on an 
accurate assessment of fracture risk could save many lives in patients with 
osteoporosis.  
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Although the risk of osteoporotic fractures is associated with many factors, 
bone mineral density (BMD) is the most important risk factor in most cases. The 
decrease of BMD has been linked to an increase of fracture risk in many studies. 
In general, one standard deviation (SD) reduction of BMD leads to about 1.6 fold 
increase of fractures depending on the site 5. However, despite the fact that BMD 
has been successfully used in the assessment of fracture risk, its value varies in 
different study populations. BMD has been linked with a different risk of fractures 
in men 6-9. Studies have also reported a null association of BMD and fractures 
among patients treated with anti-osteoporotics 10-12. Therefore, it is important to 
explore the association of BMD and fractures in specific populations with features 
that could affect the association. 
 
Women with breast cancer differ from their non-breast cancer 
counterparts in terms of osteoporosis risk. An inverse relationship between 
breast cancer and osteoporosis/fractures has been reported 13-19, (i.e. patients 
with osteoporosis/fractures are less likely to develop breast cancer and vice 
versa). In addition, the risk of developing osteoporosis in women with breast 
cancer could be changed for a variety of reasons including the breast cancer 
treatment such as aromatase inhibitor use and withdrawal of hormone 
replacement therapy. Although the underlying mechanism of the association 
between osteoporosis and breast cancer is not fully understood, estrogen may 
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play an important role. Because of a relatively high level of circulating estrogen 
found in women with breast cancer 20-25, it is speculated that elevated estrogen 
leads to a reduction of the risk of osteoporosis in this population. Indeed, 
estrogen has a proven beneficial effect on BMD 26-30 , and it has been reported 
that BMD is higher in women with breast cancer16, 31-34. However, whether the 
increased BMD results in a decreased risk of osteoporotic fracture is not certain. 
In fact, a surprising discrepancy between increased BMD and an increased 
rather than decreased risk of fractures in breast cancer women treated with 
tamoxifen 35  indicates a possibility that BMD may not be of value in the 
prediction of fracture in this patient population.  
 
To test the hypothesis that the inter-relationship among BMD, fracture, 
and breast cancer could change the role of BMD as a major predictor of fractures 
in women with breast cancer, we investigated the association of BMD and 
fracture in the elderly women who participated in the Study of Osteoporotic 
Fractures (SOF). Using women without breast cancer as the comparison group, 
we studied the value of baseline peripheral foot (calcaneal) BMD, site-specific 
BMD (hip, spine, wrist), and BMD change over time in the assessment of fracture 
risk at different skeletal sites in women with breast cancer. The findings of this 
study will enhance our understanding of the prediction of BMD on fractures and 
help to clarify confusion on the change in the risk of osteoporosis resulting from 
anti-breast cancer treatment.  
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3.3 Methods 
 
 
Study population 
 
 
The data used in this study were collected in the SOF study. The design 
and study population of that study have been described previously 26, 36. In brief, 
9704 white women aged 65 or older were recruited during the period of 1986-
1988 in four metropolitan clinical centers across the United States (Baltimore, 
Pittsburgh, Minneapolis, and Portland OR). Participants were followed-up  every 
four months by postcard or telephone; medical examinations were conducted at 
each visit every two years.   A follow-up rate of 98% was achieved for vital 
information and fracture status. Data from six visits are available for public use. 
This study was approved by the SOF study committee.  
 
Breast cancer status 
 
 The diagnosis of breast cancer was obtained from self-report by study 
participants and validated by review of their medical records. Participants with 
breast cancer before the enrollment were excluded from this analysis. Also 
collected was the date of the diagnosis; women with breast cancer were 
excluded if the diagnosis was after a fracture. In total, 563 participants were 
diagnosed with breast cancer during the SOF follow up. After the re-classification 
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of breast cancer status according to the dates of the diagnosis of breast cancer 
and fractures, 444 were identified as women who developed breast cancer 
during follow-up. Participants without a diagnosis of breast cancer during the 
follow-up were also included in data analyses (N=8525). 
 
BMD measures and fracture information 
 
Peripheral BMD measures including those at calcaneus, distal radius, and 
proximal radius were conducted at baseline (visit 1) using single photon 
absorptiometry. Subsequent measures starting at year two adopted duel X-ray 
absorptiometry and data were available at a variety of skeletal sites. However, 
only hip BMD was measured at multiple visits (2, 4, 5, 6) in the whole study 
population. BMD measures in spine and wrist were either only available at one 
visit or not measured at the last visit (visit 6) while whole body BMD was 
measured in a subset of the population. Therefore, peripheral calcaneal BMD 
was used to substitute for whole body BMD, and change in BMD was only 
calculated in the hip for these analyses.  
 
Information about incident fractures was ascertained by mail and phone 
and validated by x-ray reports or a review of pre-operative radiographs. Data 
were collected and calculated based on a specific starting visit. Spine x-rays 
were performed at baseline (visit 1) and visit 3. Prevalent spinal fractures were 
 
72 
 
determined by morphometric change compared with women without vertebral 
deformities. Data from the two visits (1 and 3) were combined and calculated as 
morphometric spine fractures.  
 
Data analysis 
 
 The general comparisons of characteristics between SOF participants who 
did and did not develop breast cancer were performed by either t test or chi 
square as appropriate. The incidence rate of fractures was defined as the 
number of fractures per 1000 person years. These rates were further stratified by 
age groups in 5-year intervals for comparisons by breast cancer status. To 
quantify the relationship among BMD, fractures, and breast cancer, Cox 
proportional hazards regression analysis was performed with breast cancer as a 
time-dependent variable, (i.e. the time before diagnosis of breast cancer was 
counted as non-breast cancer status). The overall risk of any incident fracture 
was first assessed using baseline BMD in women with breast cancer. The 
predictive value of baseline BMD in the development of breast cancer was also 
explored. Furthermore, the potential interaction of baseline BMD and breast 
cancer in the occurrence of fractures was tested. Eventually, a comprehensive 
assessment of the association between BMD and the first fracture incidence at a 
specific skeletal site (hip and wrist) was examined. Because of the lack of follow-
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up information on the timing of spine fracture, logistic regression was used for the 
estimation of BMD on spinal morphometric fractures.  
 
Three types of BMD measures were used in this study: baseline non-
specific BMD, site-specific BMD, and change in BMD. Baseline peripheral 
calcaneal BMD was used as the non-specific BMD. The site-specific BMD 
measures included distal wrist BMD and proximal wrist BMD, total hip BMD, and 
total spine BMD at visit 2. The change in BMD for the hip was calculated by 
comparing the measures at visit 6 to those at visit 2. To better describe the 
association of BMD and fracture, BMD measures were transformed and SD (per 
SD decrease) was used as the unit for the establishment of the regression 
models instead of using absolute measures. In addition, a T-score was 
calculated for each woman based on the hip BMD compared with the mean BMD 
of normal young people adopted from the National Health and Nutrition 
Examination Survey, and osteoporosis status was determined using the WHO 
(World Health Organization) standard 37, 38 (normal BMD: T-score>=-1.0; 
osteopenia (low BMD): -1>T-score>-2.5; osteoporosis: T-score<=-2.5).  
 
Based on the statistical tests, three potential confounders (age, BMI, and 
smoking status) were controlled in the analyses. Hazard ratios (HR) or odds 
ratios (OR) and 95% confidence interval (95% CI) were obtained for the 
estimation of the change of fracture risk resulting from per SD decrease of BMD. 
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Statistical significance was defined as the α=0.05 level. Analyses were carried 
out using SAS software, version 9.1 (SAS Institute, Inc., Cary, NC). 
 
3.4 Results 
 
 The characteristics of SOF participants by breast cancer status are shown 
in Table 1. Compared to women who were not diagnosed with breast cancer 
during the follow-up period, those with breast cancer were slightly younger (about 
9% more under 70 years old), heavier (weight: 69.86 kg vs 67.53 kg) and had 
higher Body Mass Indices (BMI) (27.25 vs 26.37). Both baseline calcaneal BMD 
and site-specific BMD (in wrist, hip and spine) were significantly higher among 
women who developed breast cancer, although the loss of BMD from visit 2 to 
visit 6 (BMD change) was similar to women without breast cancer. 
Correspondingly, fewer women with breast cancer had very low bone density 
with a T-score less than -2.5 SD (osteoporosis). No statistical difference was 
seen for other demographic characteristics and bone health-associated risk 
factors.  
 
 The incidence rate of fracture was about half or less for women who 
developed breast cancer than for their non-breast cancer counterparts across 
age groups. While the overall rate of fractures increased over time in women 
without breast cancer, it remained relatively stable in those who developed 
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breast cancer (Fig. 1). A higher percentage of women without breast cancer 
experienced a fracture at each skeletal site (Table 2).  
 
Analyses of the relationship of baseline BMD (calcaneal), breast cancer 
and fractures demonstrated that baseline BMD was associated with both risks of 
breast cancer and fractures (Table 3). Each SD decrease in calcaneal BMD, was 
associated with a statisticallly significant increased risk of fractures (HR=1.44, 
95% CI: 1.38-1.49) and a decreased risk of breast cancer (HR=0.85, 95% CI: 
0.76-0.95). Breast cancer itself was associated with a decreased risk of fractures 
(HR=0.59, 95% CI: 0.50-0.70) and this association was independent from 
baseline BMD (HR=0.61, 95% CI: 0.51, 0.73 after adjustment for baseline BMD). 
In addition, breast cancer status did not affect the association of baseline BMD 
and overall fracture risk (interaction: p=0.6431). 
 
 Table 4 summarizes the association of incident fractures in the hip and 
wrist with three different types of BMD measures. Unlike the association of BMD 
and fractures seen in women without breast cancer, the risk of fractures 
associated with BMD in those with breast cancer varied by skeletal sites and the 
types of BMD. Baseline calcaneal BMD did not predict hip well (HR=1.12; 95% CI: 
0.78, 1.59). Change in BMD was not associated with the fracture risk at the 
corresponding site (hip) (HR=1.05, 95% CI: 0.63, 1.72). Hip-specific BMD was 
more closely associated with the hip fractures than non-site-specific calcaneal 
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BMD (HR=1.43, 95% CI: 0.99, 2.08). A higher hazard ratio of wrist fractures in 
women with breast cancer was associated with all three BMD measures. The 
association of baseline calcaneal BMD and spine-specific BMD on morphometric 
fractures in the spine are represented in Table 5. Unlike the non-vertebral 
incident fractures, spinal fractures had a similar association with  site-specific 
(spine) and non-specific BMD (OR=1.40, 95% CI: 1.04, 1.90; OR=1.35, 95% CI: 
0.99, 1.85, respectively), but the association was not as strong as in women 
without breast cancer.   
  
3.5 Discussion 
 
BMD is the gold standard for the screening and diagnosis of osteoporosis 
37, 39, 40.  It is also perceived as the most valuable predictor of fractures in people 
with low bone density and patients with osteoporosis5. However, it has been 
reported that BMD is not well associated with fractures in some populations such 
as patients who received anti-osteoporotic therapy 10-12. In the present study, we 
investigated the association of BMD and fractures in a specific population, (i.e. 
women with breast cancer, who differ from their non-breast cancer counterparts 
in terms of the risk of fractures).  
 
Our results demonstrated that women with breast cancer have a higher 
BMD. While BMD did show a consistent association with fracture risk in women 
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without breast cancer, the association between BMD and fractures seen in 
women with breast cancer varied by skeletal sites and the types of BMD 
measures. Among the three types of BMD measures used in this study, non-
specific BMD was less efficient. Site-specific BMD in the hip was better 
associated with hip fracture, but BMD change at this site did not predict fractures 
(Table 4). Unlike incident fractures, spine morphometric fractures were predicted 
by either non-specific or spine-specific BMD (Table 5). Although BMD predicted 
wrist fractures better in women with breast cancer, it is not conclusive partially 
because of the low number of wrist fracture cases identified in this study 
population. Overall, the predictive value of BMD on fracture in women with breast 
cancer is weak. Only site-specific BMD appears to have a modest association 
with fractures in those women diagnosed with breast cancer.  
 
 The weak association of BMD and fractures in women with breast cancer 
could be attributable to multiple factors. Breast cancer itself certainly plays the 
most important role. BMD is a predictor not only for bone health but also for the 
risk of breast cancer.  Although how much their relatively higher BMD benefits 
bone health is not clear, women with breast cancer have been found to have a 
decreased risk of fractures 19 which was also demonstrated in this study. The 
inter-relationship among BMD, fractures, and breast cancer could lead to a 
change of association between BMD and fracture in women with breast cancer. 
While a low fracture incidence is likely a major reason for finding an overall lower 
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risk of fractures associated with a given risk factor, the association of BMD and 
fractures could be further weakened by breast cancer itself through a decreased 
risk of fractures that is independent from BMD (Table 3).  
 
 The different association between fractures and non-specific, site-specific 
BMD and change in BMD has been demonstrated in previous studies in general 
populations 41-44. In women with breast cancer, this difference is more apparent. 
While only site-specific BMD has a modest predictive value at the corresponding 
skeletal sites, neither the non-specific baseline BMD nor a change in BMD was 
associated with an increased risk of fracture.  
 
   
 Several limitations of this study could affect the findings. The SOF study 
was designed to study osteoporotic fractures among elderly women in general. 
Within the large cohort of 9704 participants, there are a relatively small number 
of women who developed breast cancer (N=563). Of those with breast cancer, 
less than 10% of women suffered from osteoporosis (Table 1) or wrist/hip 
fracture (Table 2). The sample size is likely an important contributor to the 
inability to detect a statistically significant association between BMD and 
fractures. In addition, due to data unavailability, analyses did not adjust for the 
breast cancer and treatment characteristics. Since some breast cancer 
treatments such as adjuvant hormonal therapy and the disease itself (bone 
 
79 
 
metastasis) are associated with the risk of fractures 45-47, the lack of this 
information prevents adjustment for potential confounding factors and adequate 
explanation of the study findings.  
 
Assessing the risk of bone fracture is of great importance in clinical 
practice. Due to the fact that BMD accounts for 75% to 85% of bone strength 48, it 
is highly related to the risk of fractures. However, bone fracture is a clinical 
outcome associated with multiple risk factors and disease conditions. Although 
BMD is the most commonly used measure in the assessment of the risk of 
fractures, other factors such as falls 49and the history of fractures 50 are also 
associated with fractures. Each risk factor, including BMD, may play a slightly 
different role in the overall risk of fractures in a given population. In women with 
breast cancer, it appears that the weight of BMD in predicting fractures is 
decreased. While the higher BMD measure and estrogen level in this population 
could be important contributors to the change in the predictive value, the lower 
risk of fractures in women with breast cancer that is independent from BMD 
indicates that breast cancer itself might have more of a role in the association of 
BMD and fractures. It is possible that this population has a different combination 
of risk factors, so that not only the role of BMD in the prediction of fracture is 
changed but the overall risk of fracture is lower. Because of the low predictive 
value of BMD shown in this study, BMD should be used cautiously, especially 
non-site specific BMD and change in BMD, to predict and monitor the risk of 
 
80 
 
fractures in women with breast cancer. Alternative measures and tools should be 
developed and studied to replace BMD. Future study to identify the unique risk 
factors in women with breast cancer is important for accurately assessing the risk 
of fracture for this patient population.  
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Table 1. Characteristics of SOF participants by breast cancer status 
 Breast Cancer 
(N=444) 
Non-Breast Cancer 
(N=8525) 
P value 
Age (%) 
     65-69 
70-74 
75-79 
80+ 
 
50.62 
32.50 
11.01 
5.86 
 
42.57 
31.14 
16.22 
10.06 
<0.0001 
Education (%) 
Elementary 
High school 
College training 
Post graduate  
 
0.38 
65.19 
20.96 
13.46 
 
1.25 
66.98 
21.53 
10.24 
0.4375 
Smoking (%) 
Never 
Past 
Current 
 
64.11 
27.32 
8.57 
 
60.09 
29.93 
9.98 
0.0632 
Physical activity(past wk) (%) 
Yes 
No 
 
71.23 
28.77 
 
67.43 
32.57 
0.0619 
Weight (kg)  69.29 66.88 <0.0001 
BMI (mean±SD) 27.05 26.38 <0.0001 
Waist/hip ratio  0.81 0.81 0.7357 
Calcium use (%) 
Never 
Past 
Current 
 
47.07 
9.06 
43.87 
 
49.45 
7.93 
42.61 
0.3815 
Estrogen use (%) 
Never 
Past 
Current 
 
93.68 
6.32 
0.00 
 
93.74 
6.10 
0.17 
0.9209 
History of fall (%) 
Yes 
No 
 
71.35 
28.65 
 
69.73 
30.27 
0.4170 
Baseline Calcaneal BMD (gm/cm2) 0.42 0.40 <0.0001 
Site-specific BMD (gm/cm2) 
Wrist 
     Distal radius 
     Proximal radius 
Hip 
Spine 
 
 
0.38 
0.66 
0.79 
0.88 
 
 
0.36 
0.63 
0.76 
0.86 
 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
BMD change (Hip, %) -4.90 -4.61 0.4747 
Osteoporosis status (%) 
     Normal (T>= -1) 
     Osteopenia (-2.5<T<-1) 
     Osteoporosis (T<=-2.5) 
     Missing  
 
34.46 
46.89 
9.06 
9.59 
 
24.12 
44.36 
14.45 
17.07 
0.8464 
Arthritis (%) 
     Yes 
     No 
 
63.62 
36.38 
 
63.17 
36.83 
0.8521 
Diabetes (%) 
     Yes 
     No 
 
7.71 
92.29 
 
6.93 
93.07 
0.5281 
Anti-osteoportics (%) 
     Bisphosphonate 
            Yes 
            No 
     Reloxifene 
            Yes 
            No 
 
 
4.95 
95.05 
 
0.00 
100.00 
 
 
5.20 
94.80 
 
0.11 
99.89 
 
0.8323 
 
 
0.5313 
All-cause death (%) 
     Yes 
     No 
 
37.84 
62.16 
 
48.95 
51.05 
<0.0001 
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Table 2. Fractures at different skeletal sites among SOF participants by breast cancer 
status 
Breast Cancer 
(N=444) 
Non-Breast Cancer 
(N=8525) 
 
No. of Fracture % No. of Fracture % 
P 
value 
Wrist       
Hip       
Spine (morphometric)     
24 
42 
74 
5.41 
9.46 
17.01 
881 
1110 
2148 
10.19 
12.84 
25.18 
0.0010
0.0367
0.0001
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Fig 1. Fracture incidence among SOF participants by breast  
cancer status 
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Table 3. Association of baseline BMD (per SD decrease in calcaneal BMD), breast 
cancer and fractures among SOF participants  
Fractures (any) Breast Cancer  
 HR   (95% CI) HR  (95% CI) 
Baseline BMD 1.44 (1.38, 1.49)  0.85 (0.76, 0.95) 
Breast cancer          
Breast cancer+baseline BMD 
0.59 (0.50, 0.70) 
0.61 (0.51, 0.73) 
   
Breast cancer*baseline BMD 0.96 (0.82, 1.13)    
Adjusted for age, BMI, and smoking status. 
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Table 4. Association of BMD (per SD decrease) and fractures among SOF participants  
Hip  Wrist 
Breast cancer Non-breast cancer Breast cancer Non-breast cancer
 
 
 HR (95% CI) HR (95% CI) 
 
P value
HR (95% CI) HR (95% CI) 
 
P value
Baseline BMD 1.12(0.78, 1.59) 1.42 (1.32, 1.52) 0.0754 1.93 (1.18, 3.13) 1.57 (1.44, 1.70) 0.0005
Site-specific BMD      
       Hip 
       Distal radius 
       Proximal radius 
 
1.43 (0.99, 2.08)
 
1.91 (1.76, 2.09) 
 
0.3637
 
 
1.75 (1.20, 2.79)
1.58 (1.01, 2.47)
 
 
1.69 (1.56, 1.82) 
1.39 (1.29, 1.50) 
 
 
0.0016
0.0006
BMD change (Hip) 1.05 (0.63, 1.72) 1.42 (1.29, 1.55) 0.1319    
Adjusted for age, BMI, and smoking status 
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Table 5. Association of BMD (per SD decrease) and spinal  
morphometric fractures  
Breast cancer Non-breast cancer  
OR (95% CI) OR (95% CI) 
Baseline Calcaneal BMD 1.40 (1.04, 1.90) 1.73 (1.63, 1.84) 
Site-specific BMD (spine) 1.35 (0.99, 1.85) 1.72 (1.61, 1.84) 
Adjusted for age, BMI, and smoking status. 
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CHAPTER IV 
 
Coronary heart disease among tamoxifen-treated postmenopausal women 
with breast cancer  
 
4.1 ABSTRACT 
 
Postmenopausal women with breast cancer are members of a population that is 
also at high risk of coronary heart disease (CHD). Adjuvant tamoxifen therapy 
has been shown to have a beneficial effect on the cardiovascular system. 
However, the association between tamoxifen and CHD reported in previous 
studies was either borderline or inconsistent. We conducted a retrospective study 
in four integrated healthcare delivery systems to investigate the association of 
tamoxifen use and the incidence of CHD among 820 postmenopausal women 
with breast cancer. This association was further explored with stratification of the 
duration of tamoxifen use to examine the dose-response association of tamoxifen 
therapy and CHD. Compared to patients without tamoxifen, the overall incidence 
of CHD in tamoxifen-treated patients was lower (adjusted HR=0.60, 95% CI: 
0.40-0.88). For each year of tamoxifen use, there was a statistically significant 
decrease in the risk of CHD (HR=0.90, 95% CI: 0.82-0.98). Further analyses 
categorized by length of tamoxifen use showed that an apparent association with 
a decreased CHD risk was found in patients who received tamoxifen for two to 
five years (HR=0.54, 95% CI: 0.33-0.86). No association was detected after the 
discontinuation of tamoxifen therapy. In summary, tamoxifen reduces the risk of 
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CHD in postmenopausal women with breast cancer in a dose-dependent manner. 
The favorable association is particularly evident in those patients who continued 
their tamoxifen use for at least two years.  
 
KEYWORDS: Tamoxifen; Breast cancer; Coronary heart disease. 
 
4.2 INTRODUCTION 
 
Coronary heart disease (CHD) and breast cancer are two of the leading 
diseases threatening women’s health.1, 2 Although the etiologies of both diseases 
are not well-understood, the age and sex-dependent risk of these two diseases 
indicates that female hormones play an important role. While the risk of CHD 
increases after menopause,3-5 high estrogen exposure has been linked to a 
protective effect on CHD as well as an increased risk of breast cancer. 6-12 Since 
postmenopausal women are also at high risk for CHD, a treatment that 
suppresses the action of estrogen in the breast while mimicking an estrogenic 
effect on coronary arteries might provide additional benefit to these patients.  
  
 Tamoxifen, the most commonly used and successful SERM (Selective 
Estrogen Receptor Modulator) in the history of breast cancer treatment, is 
potentially such a candidate. Unlike estrogen, tamoxifen is a chemically synthetic 
agent that lacks the steroid structure but can still bind to estrogen receptors and 
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exert tissue-specific actions.13, 14 Since its introduction into clinical practice in 
1978, tamoxifen has been shown to effectively reduce the risk of breast cancer 
recurrence and improve survival in women at all stages of breast cancer due to 
its anti-estrogenic effect.15-17 Tamoxifen has also been reported to have a 
beneficial effect on the cardiovascular system where it acts as an estrogen 
analog in postmenopausal women with breast cancer. For example, tamoxifen 
has been found to lower serum lipid levels18-21 , a proven risk factor for CHD. 
More directly, it has been linked with a reduced risk of CHD in several clinical 
trials.22-25 Recently, an observational study was also able to reproduce the benefit 
associated with tamoxifen on CHD.26  
 
 Despite the fact that the current evidence appears to suggest that 
tamoxifen may reduce the risk of CHD in postmenopausal women with breast 
cancer, the beneficial effects found have been either borderline or not statistically 
significant.27 Inconsistent findings in both randomized controlled trials 28, 29and 
observational study settings30 have also been reported. In addition, the majority 
of the evidence was not based on clinical outcomes such as . myocardial 
infarction and angina.31 Therefore, the association of tamoxifen and CHD needs 
further investigation.  
 
 In the present study, we explored the association of tamoxifen use and 
CHD incidence in postmenopausal women with breast cancer in four integrated 
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healthcare delivery systems. To better estimate the magnitude of the potential 
benefit associated with tamoxifen on CHD, we also studied the dose-response 
relationship based on the duration these patients received tamoxifen. As 
adjuvant hormonal therapy switches from tamoxifen to the third generation 
aromatase inhibitors (AIs),32 our study provides important information on the 
risk/benefit ratio of this switch in the treatment of breast cancer for 
postmenopausal women who are also exposed to a high risk of CHD.  
 
 
4.3 MATERIALS AND METHODS 
 
Data Sources and Study Population 
 The data sources used in this study have been described previously.33-35 
In brief, patients from four sites of the Cancer Research Network (CRN), were 
the targeted study population. Newly diagnosed breast cancer patients aged 55 
or above (between January 1, 1996 and December 31, 1997) were identified and 
followed for up to seven years. Initially, 897 patients were eligible for this study. 
After the exclusion of those with CHD before the diagnosis of breast cancer, 809 
patients were included in the final study population.  
 
Identifying breast cancer, tamoxifen use, CHD, and other parameters 
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 Among the four study sites, two (Henry Ford Health System, Detroit, MI; 
and Kaiser Permanente Northern California, San Francisco/Sacramento, CA) 
have access to tumor registries while the other two (HealthPartners, 
Minneapolis/St. Paul, MN; Fallon Clinic, Worcester, MA) do not. Breast cancer 
cases were identified through either tumor registry or a chart review. All cases 
were confirmed by trained medical abstractors by a review of  patients’ medical 
records.35 The criterion of the American Joint Commission on Cancer was used 
for categorization of  the stage of breast cancer {0 (in-situ), I, II, III, other (IV or 
unknown)} at diagnosis.  
 
 Tamoxifen use information was collected from both chart review and 
automated pharmacy data. Patients with an indication of tamoxifen use in either 
source were considered tamoxifen users. For the duration of tamoxifen use, if the 
discontinuation was recorded in chart review, this date was used for the 
calculation of the years of tamoxifen treatment received. Otherwise, the date of 
last prescription of tamoxifen in pharmacy data plus the days of supply were 
extracted. Based on the actual length of tamoxifen use, a variable reflecting the 
years of therapy was created and categorized in four levels (non-tamoxifen, 
tamoxifen: <2 years, 2-5 years, and >5 years).  
 
 CHD cases were identified from inpatient and outpatient automated 
utilization data using a combination of diagnosis and procedure codes.36-39 Three 
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coding systems {The International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM),; The Current Procedural Terminology (CPT); 
and The Healthcare Common Procedure Coding System (HCPCS)} were 
adopted for the data extraction. ICD-9-CM codes '410-414' and '429' were used 
to identify MI and angina/ischemic heart disease; the procedure codes '3601', 
'3602', '3605', '3609' (ICD-9-CM), '3351', '33521-33523', '33533', '33535', '33536' 
(CPT) were applied for identifying coronary artery bypass graft (CABG); and the 
codes '361x-36.3x’ (ICD-9-CM), '92980-92984', '92995', '92996' (CPT), plus 
'G0290', 'G0291' (HCPCS) were adopted for extracting percutaneous coronary 
intervention (PCI). In patients with either one diagnosis or procedure code and 
outpatients with two diagnosis codes or one procedure code were defined as 
patients with CHD.37  
 
 Other information abstracted from medical records include general 
demographic characteristics (age and race), breast cancer specific data 
(hormone receptor status and cancer treatments), and comorbidity information. A 
modified Charlson score40 was calculated and categorized into four levels (0, 1, 2, 
3 or above) after weighting as originally developed. Since there is a possibility 
that patients who received tamoxifen also actively seek other health care 
services, we used preventive services as an indicator for this potential 
confounding factor affecting the association of tamoxifen and CHD. Preventive 
services received by the study population were collected from automated 
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utilization data. Similar to the identification of CHD, ICD-9-CM, CPT, AND 
HCPCS codes were used to identify receipt of mammograms, colorectal cancer 
screening, influenza vaccination, and BMD testing from the automated utilization 
data.  
 
Data analyses 
 The dataset was first checked for outliers. Since the exclusion of those 
outliers with a high deviance residual did not change predicted value for 
outcomes, we included all patients in the data analyses (Appendix 1). Descriptive 
statistics were used to compare the characteristics of tamoxifen users and non-
users. All variables included in this study were either dichotomous or categorical, 
thus, chi square tests were performed to identify differences between patients 
with and without tamoxifen therapy. Tamoxifen use was treated as a time-
dependent variable in this study. The effect of tamoxifen on CHD was also 
analyzed based on the timing of tamoxifen use, (i.e., before, during, and after 
tamoxifen therapy). The time prior to the start of tamoxifen therapy was 
categorized as non-tamoxifen use. For CHD cases, time to event was calculated 
from the time of diagnosis of breast cancer to the CHD event. For those patients 
who did not develop CHD during the follow-up period of study, time was 
estimated to the date of disenrollment, last day of follow-up, or death, whichever 
came first. Cox proportional regression analyses were performed to calculate the 
difference of the risk of developing CHD in patients with tamoxifen versus those 
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without tamoxifen. The association of tamoxifen and CHD was addressed 
separately by the timing of tamoxifen use. While we focused on the period of time 
when tamoxifen was actually used, the CHD incidence after tamoxifen use was 
also explored. Since there is a possible residual effect after the discontinouation 
of tamoxifen, we did not group the post-tamoxifen time into the non-tamoxifen 
category but evaluated it as an independent time period. The crude hazard ratio 
(HR) was first obtained, followed by the establishment of a model adjusted for 
potential confounding factors. The inclusion of potential confounding variables 
was based on clinical significance and statistical considerations. After testing the 
adjusted model with different combinations of potential confounding factors, the 
final model was established with demographic variables (age and race), disease 
specific factors (cancer stage and surgery), and preventive services (colorectal 
cancer screening and influenza vaccination). The full model did not violate 
proportional hazard assumption as demonstrated by BPHREG procedure in SAS 
(Appendix 2). All analyses were performed using SAS for Windows, Version 
9.1.3 Service Pack 4 (SAS Institute, Inc., Cary, NC).  
 
 
4.4 RESULTS 
 
 The general comparison of patient characteristics is presented in Table 1. 
Similar proportions of patients were seen in each age category between the 
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tamoxifen and non-tamoxifen groups. Slightly more white patients received 
tamoxifen (82.02% vs. 80.79%), and a somewhat higher percent of black patients 
were non-tamoxifen users (11.24% vs. 10.15%), but these differences are not 
statistically significant (p=0.7152). Although data for hormone receptor status 
{estrogen receptor (ER) and progestin receptor (PR)} are only available at two of 
four sites, a much higher percent of patients with tamoxifen compared to those 
without tamoxifen were ER/PR positive (84.07% vs. 39.38%, p<0.0001), 
suggesting the reliability of these data. Patients who did not receive tamoxifen 
therapy were more often diagnosed at in situ stage (stage 0: 30.34% vs. 2.21%), 
were more likely to receive breast conserving surgery (BCS) (60.39% vs. 49.10%) 
and had less severe comorbidity (Charlson score 0: 65.17% vs. 69.76%); while 
patients in both tamoxifen and non-tamoxifen groups were almost equal in 
receiving chemotherapy and radiotherapy. The utilization of preventive services 
differed between tamoxifen users and non-users. Among the four most frequently 
used services, patients with tamoxifen were more likely to also obtain colorectal 
cancer screening (60.71% vs. 49.44%, p=0.0014) and influenza vaccination 
(35.54% vs. 29.49%, p=0.0694), but are similar to those without tamoxifen in 
receipt of mammograms and bone mineral density (BMD) testing.  
 
 The identified CHD cases stratified by coding systems are summarized in 
Table 2. Of the total 160 CHD cases identified in this study population, 138 were 
found through diagnosis codes of which most (117) were from outpatient data. 
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Using procedure codes for PCI and CABG identified fewer than half of the CHD 
events (56/160=35.00%); while the majority of cases were also found in the 
outpatient data (36/56=64.28%). Comparing CHD incidence in patients with 
tamoxifen to those without tamoxifen, there is no significant difference when 
restricted to the cases identified using diagnosis codes from either inpatient data 
(11.04% vs. 9.83%, p=0.5789) or outpatient data (15.01% vs. 13.76%, p=0.6169) 
as well as the two combined (17.44% vs. 16.57%, p=0.7452). However, the 
percent of CHD found though procedure codes differed between tamoxifen users 
and non-users (6.18% vs. 7.87%), especially for those identified from inpatient 
data (2.43% vs. 3.65%). Overall, the CHD incidence is almost identical in 
patients who did or did not receive tamoxifen therapy (19.87% vs. 19.66%).  
  
 The quantitative risk of CHD in patients with tamoxifen compared to those 
without tamoxifen was estimated using a Cox proportional regression model, and 
the results are presented in Table 3. Although the overall incidence of CHD in 
patients with tamoxifen is almost identical to non-tamoxifen users (44.18 vs 46.05 
per 1000 person years); the final estimate of the risk of CHD differs. For each 
year of tamoxifen use, there was a statistically significant decrease of the risk of 
CHD (HR=0.90, 95% CI: 0.82-0.98). For patients who received tamoxifen for less 
than two years, the risk of CHD could not be accurately assessed because of the 
small number of cases (N=3). A large reduction in risk was seen in patients on 
tamoxifen for two to five years (adjusted HR=0.54, 95% CI: 0.33-0.86). For 
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patients who continued tamoxifen beyond the five years of standard therapy, the 
association of tamoxifen and CHD was inconclusive (adjusted HR=0.77, 95% CI: 
0.44-1.25). Overall, the risk of CHD in patients on tamoxifen therapy is lower than 
non-tamoxifen users (adjusted HR=0.60, 95% CI: 0.40-0.88). The benefit 
associated with tamoxifen on CHD was only observed during tamoxifen use.  
  
4.5 DISCUSSION 
 
 Tamoxifen has been perceived to have a beneficial effect on CHD in 
postmenopausal women with breast cancer because of its estrogen-like action. 
However, the current evidence is not consistent, and the effect is not well 
determined.27, 31 In the present study, we examined the relationship between 
tamoxifen use and CHD in postmenopausal breast cancer patients in multiple 
community-based health delivery systems. Our results demonstrated an overall 
benefit associated with tamoxifen use on CHD. Furthermore, the benefit is dose-
dependent. The reduction of CHD risk was more likely seen in patients who 
received tamoxifen for at least two years. No reduction was found after the 
discontinuation of tamoxifen therapy. 
 
 Previous studies have reported a potential benefit associated with 
tamoxifen on the risk of CHD.27 Most of these studies were clinical trials in a 
diverse patient population. On average, 26% decrease of the risk of CHD was 
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found among patients with tamoxifen therapy (RR=0.74, 95% CI: 0.47-1.16), but 
the decrease lacks statistical significance. In those trials conducted specifically in 
postmenopausal women with breast cancer, the magnitude of the association of 
tamoxifen and CHD was even smaller (RR=0.89, 95% CI: 0.48-1.64). While the 
findings could reflect the real effect of tamoxifen on CHD, these results may be 
biased by the fact that in most studies the tamoxifen therapy did not complete a 
standard regimen with an average exposure of 2.2 years among postmenopausal 
patients. In the limited number of observational studies, the results are even 
more controversial.41 The association of tamoxifen and CHD in patients with 
breast cancer treated in community settings needs to be clarified.  
 
 One advantage of our study is that we investigated the relationship of 
tamoxifen and CHD among women with health insurance receiving health care in 
integrated systems. All patients included in this study have equal access to 
health care so that the likelihood of under-service is lessened. This enables us to 
assess the association of tamoxifen and CHD in a community setting where the 
length of the tamoxifen use is the actual treatment time rather than an artificial 
cutoff by study design. Thus, we identified a study population with an average 
use of tamoxifen for 3.5 years, much longer than most previous studies. In 
addition, the geographically diverse population reduces bias. The results 
generated from this study population (overall HR: 0.60) are within the range of 
summarized findings from multiple clinical trials 27(0.48-1.64). In addition, we 
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were able to demonstrate a dose-dependent relationship of tamoxifen use and 
risk of CHD in postmenopausal women with breast cancer, which not only 
explains the failure of the observation of protection in some previous studies, but 
also furthers our understanding of the benefit associated with tamoxifen on CHD.  
  
 Nevertheless, our study is limited by several factors. While we used a 
combination of chart review and automated data extraction supplemented with 
the confirmation of medical records and pharmacy data for identifying breast 
cancer and tamoxifen use, the search for CHD cases was solely dependent on 
automated utilization data. However, unlike many studies which simply adopt 
diagnosis codes for identifying CHD, we conducted a comprehensive search in 
both inpatient and outpatient data bases using not only diagnosis codes but 
procedure codes as well, and thus, avoided missing some cases. More 
importantly, without the confirmation from medical records, it is possible that 
some cases were mistakenly identified. Due to the lack of information of 
characteristics such as smoking and serum cholesterol levels, we were not able 
to adjust all risk factors known to be relevant to CHD. The lack of access to the 
data about hormone receptor status at two study sites prevented us from further 
studying the association of tamoxifen and CHD in patients who are hormone 
receptor positive. Some important information about medication associated CHD 
specific risk factors such as statin and aromatase inhibitor use was not available, 
and thus, not adjusted in this study, which could potentially either exaggerate 
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(biased by statins) or underestimate the benefit of tamoxifen use (biased by 
aromatase inhibitors) on CHD.  
  
CHD is the leading cause of death in postmenopausal women.1 Together 
with breast cancer, the most common cancer and the second leading cause of 
cancer death in women2  postmenopausal patients with breast cancer are at 
heightened risk. Our study agrees with previous reports of the benefit associated 
with tamoxifen on CHD and further demonstrates a dose-dependent pattern of 
beneficial effect. Therefore, patients who receive the standard five years of 
tamoxifen therapy could benefit from a significant decrease in risk of CHD. Since 
there is a high prevalence of CHD in postmenopausal women, a slight reduction 
of the risk of CHD could save many of them from this lethal disease. While 
tamoxifen has been recently replaced by more potent 42 AIs as the first choice of 
adjuvant hormonal therapy for breast cancer, the lack of similar beneficial effect 
of the latter on CHD raises the importance of an assessment of overall 
risk/benefit ratio during recommendations for breast cancer treatment. For a 
postmenopausal patient with breast cancer who is known to be at a high risk of 
CHD, tamoxifen could outweigh AIs and thus be recommended as the first choice 
of adjuvant hormonal therapy. In addition, because the significant benefit of 
tamoxifen on CHD appears to occur in patients on tamoxifen for at least two 
years, a good adherence to the standard five-year tamoxifen therapy would 
confer more benefits to those who tolerate the treatment. Future study 
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investigating the benefit of tamoxifen therapy on CHD is necessary to determine 
the overall risk/benefit ratio in postmenopausal women with breast cancer.  
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Table 1. Characteristics of patients in IMPACT study by tamoxifen use status 
 Tamoxifen 
(N=453) 
Non-Tamoxifen 
(N=356) 
P value 
Age  
      55-59 
      60-64 
      65-69 
      70-74 
      75-79 
      80+ 
 
20.09 
17.44 
17.88 
17.66 
17.44 
9.49 
 
21.35 
15.73 
17.42 
16.57 
16.29 
12.64 
0.6552 
Race 
      White 
      Hispanic 
      Black 
      Asian/Pacific 
      Unknown 
 
80.79 
1.99 
10.15 
4.42 
2.65 
 
82.02 
0.84 
11.24 
3.37 
2.53 
0.7152 
Hormone receptor status  
(ER/PR)† 
      Positive 
      Negative 
      Unknown 
 
(n=226) 
84.07 
4.87 
11.06 
 
(n=193) 
39.38 
16.06 
44.56 
<0.0001 
Cancer Stage 
      0 
      I 
      II 
      III 
      Other 
 
2.21 
48.79 
33.55 
9.27 
6.18 
 
30.34 
43.82 
16.01 
3.09 
6.74 
<0.0001 
Surgery 
      BCS 
      Mastectomy 
      None 
 
49.01 
45.47 
5.52 
 
60.39 
35.96 
3.65 
0.0014 
Chemotherapy 
      Yes 
      No 
 
22.08 
77.92 
 
17.42 
82.58 
0.1004 
Radiotherapy 
      Yes 
      No 
 
54.30 
45.70 
 
51.40 
48.60 
0.4123 
Charlson score 
      0 
      1 
      2 
      3 
 
69.76 
20.09 
5.30 
4.86 
 
65.17 
20.79 
7.58 
6.46 
0.0423 
Duration of Tamoxifen use (years)  
      <2    
      2-5   
      >5   
 
28.48 
50.33 
21.19 
N/a N/a 
Mammogram       
      Yes 
      No 
 
64.90 
35.10 
 
67.70 
32.30 
0.4045 
Colorectal cancer screening 
      Yes 
      No 
 
60.71 
39.29 
 
49.44 
50.56 
0.0014 
Influenza vaccination 
      Yes 
      No 
 
35.54 
64.46 
 
29.49 
70.51 
0.0694 
BMD testing 
      Yes 
      No 
 
26.49 
73.51 
 
24.71 
75.28 
0.5675 
†   Data not available at two HMO sites (Fallon Clinic, MA and Henry Ford Health, MI). 
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Table 2. Identified CHD among the patients in IMPACT study 
Coding system used Number of 
cases† 
Tamoxifen  
(%) 
Non-Tamoxifen 
(%) 
P value 
Diagnosis 
        Inpatient 
        outpatient 
138 
85 
117 
17.44 
11.04 
15.01 
16.57 
9.83 
13.76 
0.7452 
0.5789 
0.6169 
Procedure (PCI, CABG)
        Inpatient 
        Outpatient 
Diagnosis+Procedure 
56 
24 
36 
160 
6.18 
2.43 
4.42 
19.87 
7.87 
3.65 
4.49 
19.66 
0.3492 
0.3089 
0.9567 
0.9422 
†These numbers are not mutually exclusive.  
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Table 3. Comparison of CHD incidence in patients with versus without tamoxifen therapy 
HR (95% CI)  Number of 
Cases 
  CHD Event 
  (/1000 pys) Crude Adjusted† 
Non-Tamoxifen 70   46.05 Reference Reference 
Tamoxifen 
     Before treatment 
     During treatment  
          <2 years 
          2-5 years 
          >5 years 
          Each year    
     After treatment     
90 
17 
44 
  3 
25 
16 
N/a 
29 
  44.18 
102.27 
  31.98 
  31.43 
  29.17 
  37.82 
  N/a 
  58.59   
0.64 (0.45, 0.93)* 
1.45 (0.82, 2.67)  
0.64 (0.45, 0.93)* 
0.51 (0.16, 1.64) 
0.59 (0.38, 0.93) 
0.79 (0.46, 1.35) 
0.92 (0.85, 0.99)* 
1.08 (0.71, 1.67) 
0.60 (0.40, 0.88)*
1.50 (0.81, 2.80) 
0.60 (0.40, 0.88)*
0.48 (0.15, 1.54) 
0.54 (0.33, 0.86)*
0.77 (0.44, 1.25) 
0.90 (0.82, 0.98)*
1.04 (0.66, 1.62) 
† Adjusted for age, race, surgery, cancer stage, colorectal screening, and influenza vaccination.  
Asterisk (*) indicates p<0.05. 
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CHAPTER V 
 
 
Summary 
 
 
5.1 Study findings 
 
 
 Previous studies demonstrated that tamoxifen preserved BMD in 
postmenopausal patients with breast cancer. This preservation is evident in the 
hip and spine but not detectable in the wrist. However, observations documented 
in the few available studies regarding the association of tamoxifen and fractures 
showed an unexpected increase of risk of fractures in patients treated with 
tamoxifen.  
 
We investigated the relationship of tamoxifen and fractures in the three 
common fracture skeletal sites (spine, hip, and wrist) plus the combined sites 
(total body) in postmenopausal women with breast cancer in an insured 
population. Our results showed that the association of tamoxifen and fracture 
incidence varied at different skeletal sites. Although the associations between 
tamoxifen and fractures in the spine (HR=0.40, 95% CI: 0.09-1.85), wrist 
(HR=2.49, 95% CI: 0.88-7.06), and total body (HR=0.87, 95% CI: 0.49-1.55) 
were imprecise and inconclusive, an apparent reduction of the risk of fracture 
was found in the hip (HR=0.41, 95% CI: 0.17-1.03) with borderline statistical 
significance (p=0.0565).  Although the effect estimates, especially in the spine 
where subtle fractures are likely to be under-diagnosed, are imprecise, the 
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pattern of the association of tamoxifen and fractures found in this study was 
similar to its benefit on BMD in a recent systematic review of 27 studies which 
demonstrated a site-specific preservation on spine and hip but not wrist. In 
addition, the reduced fracture risk seen in this study was consistent with the 
findings reported in a breast cancer prevention setting using tamoxfien, further 
supporting the possibility of a benefit associated with tamoxifen on fractures. 
 
BMD is the gold standard for the screening and diagnosis of osteoporosis.  
It is also perceived as the most valuable indicator for the prediction of fracture 
risk in both people with low bone density and patients with osteoporosis. 
However, it has been reported that BMD did not predict fractures well in some 
populations such as patients who received anti-osteoporotic therapy.  
 
Using SOF data, we demonstrated that, while BMD did show a consistent 
association with fracture risk in women without breast cancer, the association of 
BMD and fractures seen in women with breast cancer varied by different skeletal 
sites, osteoporosis status, and the type of BMD measure. Among the three types 
of BMD measures used in this study, non-specific BMD has a weak association 
with fractures. Site-specific BMD (hip) had a stronger association with hip 
fracture, but BMD change at this site was not associated with fractures. Unlike 
non-vertebral incident fractures, the spine morphometric fracture had a similar 
association with either non-specific or spine-specific BMD. Overall, the 
association of BMD and fractures in women with breast cancer is weak. Only 
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site-specific BMD appears to have a consistently modest association with 
fractures in those women diagnosed with breast cancer.  
 
In addition to bone health, tamoxifen has been perceived to have a 
beneficial effect on CHD in postmenopausal women with breast cancer because 
of its estrogen-like action. However, the current evidence is not consistent, 
especially in observational settings, and the effect is not fully characterized. We 
examined the relationship between tamoxifen use and CHD in postmenopausal 
breast cancer patients in a large managed care system with multiple study sites. 
Our results demonstrated an overall protective association with tamoxifen use on 
CHD (HR=0.60, 95% CI: 0.40-0.88). In addition, the association of tamoxifen and 
CHD is dose-dependent. The longer a patient received the tamoxifen therapy, 
the more likely this person would have a lower incidence of CHD. 
 
The protective association for tamoxifen with bone and CHD in this study 
is likely due to the fact that tamoxifen is a selective estrogen receptor modulator 
which has tissue-specific actions. Tamoxifen acts as an estrogen antagonist in 
breast cells and thus suppresses the cancer cell proliferation stimulated by 
estrogen. In other tissues such as bone, uterus, and cardiovascular system, 
tamoxifen is an estrogen agonist and exhibits some estrogen-like effects. 
Although still controversial, estrogen itself has been linked to the protection 
against bone loss and a low risk of CHD. Since tamoxifen can mimic estrogen in 
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bone and cardiovascular system it could reduce the risk of osteoporosis and 
CHD. Whether there are other mechanisms underlying the protective association 
we observed of tamoxifen on bone and CHD is not clear but certainly can not be 
excluded. 
 
5.2 Conclusions 
 
In the current attempt to investigate the association of tamoxifen and bone 
and heart health using two cohorts of postmenopausal women, I detected a 
possible benefit associated with tamoxifen use on fractures in the hip, the 
fracture site with high morbidity and mortality. I also found that BMD did not 
predict the risk of fracture well in postmenopausal women with breast cancer. In 
addition, I demonstrated that tamoxifen was associated with a reduced risk of 
CHD in postmenopausal women with breast cancer in a dose-dependent manner. 
An apparent benefit was seen in those patients who receive tamoxifen therapy 
for at least two years.  
 
Based on the findings, I conclude that the discrepancy between BMD and 
fractures reported in previous studies among tamoxfen-treated postmenopausal 
women with breast cancer could be an artifact possibly resulting from factors 
such as the complexity of patient population, the suitability of controls, the length 
of tamoxifen use, the accuracy of identification of fractures, and the short follow-
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up. The weak association of BMD and fractures in breast cancer patients as 
demonstrated in my study could also contribute to the discrepancy. I also 
conclude that tamoxifen may have a beneficial effect on CHD if a patient receives 
tamoxifen for two years or longer. Thus, tamoxifen could provide additional 
benefits to postmenopausal women with breast cancer when they are at high risk 
of bone fractures and/or CHD.  
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Appendix 1 
 
Identifying outliers and testing their influence on the association of tamoxifen use (each year) and CHD 
 
 
HR=0.90 
(All data points included)
HR=0.91 
(Most influential outliers excluded)  
 
126 
 
Appendix 2 
 
Test of proportional hazard assumption 
 
Supremum Test for Proportionals Hazards Assumption
Variable Maximu
m 
Absolute
Value
Replication
s
See
d 
Pr > 
MaxAbsV
al
tamoxifen 1.1931 1000 19 0.1330
Age_ca2Ageca6064 1.1676 1000 19 0.2670
Age_ca2Ageca6569 1.0858 1000 19 0.4610
Age_ca2Ageca7074 1.4254 1000 19 0.1950
Age_ca2Ageca7579 1.0253 1000 19 0.5950
Age_ca2Ageca80more 1.0368 1000 19 0.4330
RACE_C2 0.7977 1000 19 0.2980
RACE_C3 0.6758 1000 19 0.6880
RACE_C4 0.6875 1000 19 0.3630
RACE_C7 0.7621 1000 19 0.4310
surgerytypeBCS 3.0843 1000 19 0.2590
surgerytypeMastecto
my 
3.2668 1000 19 0.2120
cancer_stage21 1.2395 1000 19 0.5800
cancer_stage22 1.8427 1000 19 0.1240
cancer_stage23 1.2446 1000 19 0.3160
cancer_stage24 1.4196 1000 19 0.1850
colorec1 0.6830 1000 19 0.7560
influ1 0.5619 1000 19 0.9190
   
 
